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Abstract
The ipomoeassin family of resin glycosides were discovered to have a high potency
against numerous cancer cell line, with ipomoeassin F being the most potent among the family of
natural products. Interestingly, one of the few differences between ipomoeassin F and the other
compounds is the length of the fatty-acid derived aglycon. As the mechanism of action for this
family of resin glycosides is unknown and didn’t have any significant COMPARE correlation
with the recorded anticancer agents in the National Cancer Institute (NCI), further SAR studies
are needed. Drawing on the differences between ipomoeassin F and the other ipomoeassins, it
seemed logical to explore the effect of the aglycon on the bioactivity of these compounds. To
achieve this, we sought to synthesize an epimer of ipomoeassin F, changing the configuration of
the sole chiral center contained in the aglycon, as well as developing a synthesis that would
enable us to modify the tail of the aglycon and explore in more depth the role of the critical
region of the molecule.
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BACKGROUND AND INTRODUCTION

1.1 Carbohydrate Derived Macrocyclic Natural Products
Macrocyclic compounds have been extensively studied and synthesized due to their
interesting biological and physicochemical properties and due to their abundance in nature.
These macrocycle-containing natural products have been the target of many synthetic organic
chemists over the years and have found diverse uses biologically, chemically, analytically, and
medically. Among these naturally occurring macrocyclic compounds are macrocycles with
embedded carbohydrates. In these structures, such as resin glycosides or other glycolipids, at
least two bonds from a monosaccharide residue form a macrocycle1,2,3. Due to the interesting
structures and bioactivity of many of these natural products, a number of carbohydrate derived
macrocycles have been synthesized, including Tricolorin A and G, Woodrosin I, Sophorolipid
Lactone, Glucolipsin, Cycloviracin B1, and Ipomoeassin A-F2. These syntheses have employed a
variety of intramolecular strategies to form the macrocyclic ring including the Diels-Alder
reaction, aldol reaction, copper catalyzed azide-alkyne cycloaddition (CuAAC), lactonization,
glycosylation4 and metathesis, both ring closing alkene metathesis (RCM) and ring closing
alkyne metathesis (RCAM)1,5. With the advancements to metathesis in recent years, this has
become a popular method for constructing large rings intramolecularly. The reaction conditions
are less harsh than many other reactions. The homogeneous transition metal catalysts can be used
in standard organic solvents, are stable at room temperature and are highly reactive under mild
conditions. Many of the catalysts also are tolerant to a wide range of functional groups and
protecting groups and exhibit good selectivity, leading them to be a quite popular choice for
many recent macrocyclic natural product syntheses.
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1.2 Resin Glycosides
Resin glycosides are a class of natural products unique to the morning glory family,
Convolvulaceae6. The Latin convolvo, from which the name of this family is derived, means
interlaced and refers to the interlacing vines of the plants. Resin glycosides are secreted from
cells in both foliar tissues and roots of this family of plants. Traditionally, these plants have been
used extensively by various cultures throughout the world for their purgative properties. The
active principles responsible for the purgative action of these botanical drugs are the unique
glycoresins7. Due to the potent biological activity many of the resin glycosides have shown and
their historical prevalence in botanical medicine, many have been isolated, characterized, and
assayed over the years. The morning glory family of flowering plants is quite extensive,
containing over 1,000 different species, and has yielded a wide variety of resin glycosides with a
host of different bioactivities. Calysolins I-XVII were isolated from Calystegia soldanella and
many showed anti-viral activity in an anti-HSV-1 assay8,9,10,11. Eleven pentasaccharide
macrocycles, aquaterins I-XI, were isolated from Ipomoea aquatica and exhibited potent anticancer activity in HepG2 liver carcinoma cells. Most of the compounds were shown to elevate
Ca2+ concentrations in the HepG2 cells, possibly contributing to the cytotoxicity observed12.
Alinosides I-IX, isolated from the seeds of Ipomoea alba, and wolcottine I and wolcottinosides IIV, isolated from Ipomoea wolcottiana, all showed potential as multidrug-resistance-modifying
agents13,14,15. Purgins I-III and Purginosides I-IV were obtained from Ipomoea purga and also
showed reversal of multidrug resistance, particularly Purgin II which enhanced vinblastine
activity more than 2,000 fold in vinblastine-resistant human breast carcinoma cells (MCF7/Vin)16,17. Cairicosides A and B were isolated from Ipomoea cairica and displayed αglucosidase inhibitory activity18. Cairicosides A-E all exhibited moderate cytotoxicity against a
2

small panel of human tumor cell lines19. The tyrianthinic acid tyrianthin series of resin
glycosides were isolated from Ipomoea tyrianthina and showed biological activity in some
central nervous system models as well as vasodilators. Tyrianthins C-E increased the sleeping
time induced by sodium pentobarbital and the release of gamma-aminobutyric acid (GABA) in
the brain cortex of mice20,21. Ipomotaosides A-D were extracted from the dried aerial parts of
Ipomoea batatas and some anti-inflammatory activity was displayed by inhibiting two isoforms
of the cyclooxygenase enzymes, COX-1 and COX-2. A xylose-containing oligosaccharide
bacterial efflux pump inhibitor, Pescaprein XVIII, was obtained from Ipomoea pes-caprae. The
resin glycoside was shown to potentiate the action of norfloxacin when treating multidrug
resistant strains of Staphylococcus aureus22.
Synthesis of Resin Glycosides
To date, there have been a number of total syntheses of resin glycosides published from
various groups. Structurally, these compounds all consist of two main regions. One being the
hydrophilic glycon moiety and the other being the hydrophobic aglycon moiety. The glycon is
composed of up to six monosaccharides, typically D-glucose, L-rhamnose, D-fucose, Dquinovose, and D-xylose, and are found in their pyranose forms. The fatty acid derived aglycon
typically is composed of either a mono- or dihydroxy C14 or C16 fatty acid which spans two or
more saccharide units to form a macrolactone. Usually a number of short-chain aliphatic acids
decorate the periphery of the saccharide core as well6.
Synthetically, these various molecules have proved challenging to synthesize and
numerous strategies have been employed to construct these natural products and their analogs.
The most notable challenge has been the formation of the macrocycle. Among the different
strategies employed over the years, the most notable and prolific are various lactonizations
3

conditions and RCM, the latter being the most favored in recent years23.
Synthesis of Calonyctin A
To date, two total synthesis of Calonyctin A (Figure 1-1) have been reported, first by
Schmidt in 1995 and by Sakairi in 2000. Calonyctin A is one of the few resin glycosides that
isn’t isolated from the morning glory family but from Calonyction aculeatum. This compound
strongly promotes the growth of various crops such as peanuts, beans, wheat, and potatoes24,25.
The structure consists of three D-quinovose and one L-rhamnose units forming a tetrasaccharide
and an 11-hydroxyhexadecanoic acid aglycon forming a 22-membered macrocycle.

Figure 1-1. Structure of the Calonyctins
Schmidt’s group was the first to synthesize the tetrasaccharidic macrolide, Calonyctin A1
(Figure 1-1). Schmidt’s strategy for the synthesis relied on appropriately protecting the four
carbohydrate residues and assembling the key tetrasaccharide fragment via a series of
glycosylations using the trichloroacetimidate donor method26. Following the tetrasaccharide
construction, desilylation with tetrabutylammonium fluoride (TBAF) and subsequent treatment
with trichloroacetonitrile and DBU furnished the tetraosyl acetimidate donor. The donor was
then coupled with the aglycon acceptor. Because the absolute stereochemistry was unknown at
the time, a racemic mixture of the acceptor was used to form a 1:1 mixture of diastereomeric
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glycosides which were separated after saponification. Macrolactone formation was then
accomplished using a Corey-Nicolaou macrolactonization, an established method for forming
macrolactones in natural products27 and has been successfully used in the synthesis of other resin
glycosides as well28. Allyl removal followed by acylation with 3-benzyloxy-2-methylbutyric acid
chloride and a final deprotection provided Calonyctin A1 for the first time25,29.

Scheme 1-1. Schmidt Synthesis of Calonyctin A1
In 2000, the Sakairi group targeted Calonyctin A2, which differs from Calonyctin A1
only in the length of the aglygon. Their approach started from the β-(1,3)-linked disaccharide,
laminaribiose in order to reduce the number of glycosylations in the synthesis. Following
appropriate protection of the disaccharide and conversion to the corresponding thioglycoside, a
glycosylation with the glucoside acceptor in the presence of NIS and a catalytic amount of TfOH
smoothly afforded the trisaccharide. After subsequent treatment with aqueous KOH, the
macrolactone was constructed by employing the Yamaguchi mixed anhydride procedure. An
additional glycosylation with the L-rhamnosyl donor completed the formation of the
tetrasaccharidic macrocycle, albeit in low yield. The allyl group was removed to allow for
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introduction of the 2-methylbutyric acid derivative and a final deprotection afforded Calonyctin
A2.

Scheme 1-2. Sakairi Synthesis of Calonyctin A2

Synthesis of the Tricolorins
Ipomoea tricolor had long been used as a cover crop in Mexican traditional agriculture
due to its ability to control weed growth. In 1993, Pereda-Miranda and co-workers isolated and
characterized the resin glycoside tricolorin A, the most abundant and easy to purify of the
tricolorins, from Ipomoea tricolor30. The isolated compound also showed significant cytotoxic
activity against P-388 lymphocytic leukemia cells and in human breast cancer cells. Its unique
structure and biological activity spurred several total syntheses. The first synthesis was
completed by Heathcock in 1997. He envisioned a coupling of two disaccharide units using a
rhamnose-rhamnose disaccharide glycosyl donor and a lactone disaccharide glycosyl acceptor.
However, he found that with the macrolactone already formed, the acceptor was too sterically
hindered to efficiently couple. In order to circumvent this issue, a new strategy was formed in
6

which the tetrasaccharide would be formed prior to macrolactonization. To prepare the
tetrasaccharide, the C-3 position of the glucose moiety was selectively acetylated to allow the
glycosylation between the rhamnosyl trichloroacetimidate donor and the C-2 hydroxyl group of
glucose. Following the glycosylation and a subsequent saponification, a one-pot Yamaguchi
macrolactonization and esterification with (S)-2-methylbutyric acid gave tricolorin A after a final
deprotection.

Scheme 1-3. Heathcock Synthesis of Tricolorin A
An additional total synthesis of tricolorin A was also published by the Yu and Hui
group31. Their strategy utilized thioglycosides as the glycosylating reagents employed in a onepot stepwise glycosylation to form the tetrasaccharide portion of the molecule. The disaccharide
macrolactone was assembled via a Schmidt glycosylation, subsequent deprotection and a
regioselective Corey-Nicolaou macrolactonization. To add the remaining carbohydrates a onepot, two step glycosylation was performed. First, the two thioglycosides were coupled using
NIS/TfOH followed by addition of the previously synthesized disaccharidic macrolactone. After
deprotection of the isopropylidene and benzylidene using DDQ, the benzyl groups were removed
by hydrogenation to afford tricolorin A29,31.
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Scheme 1-4. Hui and Yu Synthesis of Tricolorin A
Sakairi’s group chose to use a different strategy to form the macrocyclic core of
Tricolorin A. They closed the macrolactone using an intramolecular glycosylation, a strategy
they would go on to us for making Tricolorin F (Scheme 1-6). They first coupled the dodecyl
thiofucoside donor with methyl 11(S)-jalapionate and following a Zemplan transesterification
and subsequent saponification introduced the thioglucoside via an esterification reaction to give
the disaccharide in poor yield (12%). At this point, a MeOTf-promoted intramolecular
glycosylation afforded the key disaccharide macrolactone.

Scheme 1-5. Heathcock Synthesis of Tricolorin F
In addition to Tricolorin A, the Heathcock group also successfully completed the first
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synthesis of the trisaccharide macrolactone, tricolorin F in 200432. They followed a similar
synthetic strategy they had previously employed for tricolorin A33. After preparing the
disaccharide acceptor, it was glycosylated with quinovosyl trichloroacetimidate and saponified
(Scheme 1-5). The macrolactone was then formed following Yamaguchi’s procedure and a
subsequent debenzylation gave tricolorin F29,32.

Scheme 1-6. Sakairi Synthesis of Tricolorin F
The Sakairi group also completed the synthesis of tricolorin F applying the
intramolecular glycosylation strategy previously employed for tricolorin A. Following the
preparation of the disaccharide fragment, the thioquinovoside was coupled via an EDC mediated
esterification reaction to furnish the trisaccharide. An intramolecular glycosylation then
completed the macrocycle and two final deprotections gave the desired tricolorin F4,29.
Synthesis of the Merremosides
The merremosides were isolated from the tuber of Merremia mammosa (Lour.) Hall. F.
(Convolvulaceae). The plant had been used in Indonesia for treating diabetes as well as treating
throat and respiratory issues. These compounds were shown to exhibit ionophoretic activity with
the ability to transport Na+, K+, and Ca2+ across human erythrocyte membranes29.
In 2006, Yang’s group first synthesized the macrolactone core of the Merremosides34.
9

After coupling the 11(S)-jalapionate with the L-rhamnopyranosyl trichloroacetimidate donor, the
resulting rhamnoside was deacetylated and isopropylidinated to furnish the acceptor for a
subsequent glycosylation. An additional L-rhamnopyranosyl donor was prepared and coupled
with the rhamnoside acceptor to afford the desired disaccharide which was deacetylated. They
then tried to form the macrolactonization under Yamaguchi’s conditions but were unsuccessful
so the Corey-Nicolaou macrolactonization method was employed with decent regioselectivity to
complete the macrolactone core.

Scheme 1-7. Yang Synthesis of the Merremosides Core
The first complete synthesis of any merremoside family member was reported in 2014
when O’Doherty et al. achieved the de novo synthesis of merremoside D35. Using a strategy
common to the O’Doherty group, they began their synthesis from a pool of achiral starting
materials and relied on asymmetric catalysis to install the 21 stereocenters of merremoside D.
Their synthesis begins from a key pyranone building block which is obtained in 3 steps from
acetylfuran. The jalapinolic ester used for the aglycon was synthesized following a modified
asymmetric version of Heathcock’s protocol employed in his synthesis of Tricolorin A33. The
jalapinolic ester and the pyranone building block were then coupled via a stereoselective Pd-

10

catalyzed glycosylation. This enone was then converted to the rhamnopyranoside acceptor
through a Luche reduction, dihoydroxylation and a subsequent isopropylidination. An additional
glycosylation with the same pyranone precursor followed by enone reduction, benzyl protection,
alkene dihydroxylation and ester saponification gave the key disaccharide intermediate which
would be the precursor for macrolactonization. Macrolactonization was accomplished using the
Corey-Nicolaou method, however it gave the undesired regioisomer as the major product.
Fortunately, they found they could isomerize the undesired compound to the desired isomer upon
treatment with DBU in toluene. The remaining free hydroxyl group was then protected, and the
benzyl ether was cleaved to afford the disaccharide acceptor.

Scheme 1-8. O'Doherty Synthesis of Macrolactone Intermediate
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The disaccharide trichloroacetimidate donor was then prepared following a similar de
novo synthetic route. The donor and acceptor were coupled to form the desired tetrasaccharide
upon treatment with TMSOTf. The remaining acetonide and chloroacetate protecting groups
were cleaved to complete the synthesis of merremoside D in 22 longest linear steps with a 3%
overall yield35.

Scheme 1-9. O'Doherty Synthesis of Merremoside D
Ring-Closing Metathesis in the Synthesis of Carbohydrate Containing Macrolides
Synthesis of Woodrosin I
Woodrosin I, isolated from the stems of Ipomoea tuberosa L. (Merremia tuberosa (L.)
Rendle), is one of the most complex resin glycosides known36. It is a pentasaccharide with an
aglycon that spans four glucose units to form a 27-membered macrocycle37. Alois Fürstner, a
pioneer in the use of ring-closing metathesis (RCM) in the synthesis of macrocyclic natural
products, first reported the synthesis of Woodrosin I in 200237.
The Fürstner synthesis of Woodrosin I began with the preparation of the two disaccharide
glucosides38. After synthesizing the donor and acceptor, they attempted a regioselective
glycosylation at the 3’-OH position. Model studies had shown the 3’-OH functionality to be
12

much more active than the 2’-OH location which would free them from having to do additional
protection. While the glycosylation did achieve the desired regioselectivity, unexpectedly, NMR
showed the formation of an orthoester by participation of the chloroacetyl protecting group. The
chloroacetyl moiety had been chosen to be an orthogonal protecting group as well as providing
stereochemical control through neighboring group participation to achieve the desired βselectivity for the glycosylation reaction. Despite this obstacle, they attempted to carry on and
introduce the rhamnosyl moiety. However, they found the site to be too sterically congested for
the glycosylation to be successful. Before re-routing and starting over, they speculated that
perhaps forming the macrocycle first might alter the conformation enough to open up the
sterically hindered 2’-OH so that the rhamnosyl donor could freely be introduced.

Scheme 1-10. Fürstner Synthesis of RCM Precurser
Carrying forward with the synthesis, they decided they would attempt to form the
macrocycle by RCM before completing the oligosaccharide backbone. The ring closure
proceeded uneventfully and in excellent yield upon treatment with either Grubbs carbene or
13

phenylindenylidene complex in a dilute, refluxing solution of DCM. They then turned their
attention once again to introducing the rhamnose moiety. The rhamnosyl donor was particularly
labile so Schmidt’s “inverse glycosylation procedure”39 was implemented by premixing catalytic
amounts of TMSOTf in anhydrous Et2O with the acceptor before slowly adding the donor. This
time the glycosylation proceeded rather smoothly to complete the oligosaccharide backbone and
rearranged the orthoester junction to the desired β-glycosidic linkage in 60% yield. The synthesis
was completed by removing the chloroacetyl protecting group with hydrazine acetate followed
by hydrogenation over palladium on charcoal to reduce the alkene in the aglycon and cleave the
remaining protecting groups affording, for the first time, woodrosin I37,40.

Scheme 1-11. Completion of Woodrosin I
Synthesis of Tricolorin A and G (and Analogs)
As exemplar members of the Morning Glory family of resin glycosides, Tricolorin A and

14

G are obvious targets to demonstrate the flexibility and utility of ring-closing metathesis for the
synthesis of macrocycles. Though tricolorin A had been previously synthesized utilizing a
traditional macrolactonization strategy to close the ring, this approach doesn’t offer the
flexibility to easily generate the wide range of analogs needed to further advance SAR studies.
To assemble the precursor for RCM, an acetonide protected fucoside acceptor was
coupled with a glucosyl acetimidate donor via standard Lewis acid-catalyzed glycosylation
conditions. Following a deacetylation, the 3”-OH group could then be regioselectively esterified
with unsaturated carboxylic acids of varying lengths to give the desired RCM precursor and
showcase the flexibility of late-stage ring-closure for accessing a variety of analogs. The
subsequent RCM and hydrogenation proceeded smoothly to afford the macrocyclic core of
tricolorin A. The remainder of the synthesis involved glycosylation at the free 2”-OH position
with a suitably protected disaccharide acceptor and subsequent deprotection to provide tricolorin
A and its analogs of various ring sizes.
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Scheme 1-12. Fürstner Synthesis of Tricolorin Core
In addition to tricolorin A, the key intermediate 1.53 also could be used to access
tricolorin G. In order to realize this compound, intermediate 1.53 had to be deacetylated and the
more reactive C3” position was protected, allowing for the introduction of a rhamnosyl moiety at
the less reactive C2” hydroxyl group. Another base-catalyzed deacetylation freed the C2 position
of the rhamnosyl moiety for a subsequent introduction of 6-heptenoic acid ester to furnish the
RCM precursor 1.56. Once again showcasing the versatility of RCM for the preparation of
macrocycles of varying lengths, metathesis following by hydrogenation smoothly yielded the
desired compound, this time spanning three saccharide units. A final global deprotection would
then afford tricolorin G for the first time.

Scheme 1-13. Fürstner Synthesis of Tricolorin G
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Synthesis of Glycophanes

Scheme 1-14. Murphy Synthesis of Glycophanes
Glycophanes are macrocyclic hybrids of cyclophanes and carbohydrates. The synthesis of
these highly functionalized scaffolds illustrates once again the versatility of RCM for assembling
carbohydrate containing macrocycles, this time using much shorter aglycons. To prepare the first
glycophane 1.63, the Murphy group commenced with a glucuronic acid 6,1-anhydro derivative
which was used to prepare the glycoside 1.60. Treatment with oxalyl chloride furnished the
corresponding acid chloride which was reacted with phenylene-1,4-diamine to generate the
diamide. Subsequent N-methylation gave the RCM precursor 1.61. Ring closure using Grubbs
first generation catalyst smoothly afforded the desired product as a 4:1 mixture of isomers,
favoring the E-isomer. A final deacetylation gave glycophane 1.63. The authors noted that the Nmethylation of the secondary amides was crucial for achieving RCM versus cross-metathesis. It
is believed that the more conformationally restricted tertiary amide structure helps to facilitate
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the ring closure. A similar strategy was also employed to synthesize a variety of glycophane
derivatives with varying lengths of aglycons using both RCM and ring-closing alkyne metathesis
(RCAM). While using longer, more flexible alkanes and alkynes, N-methylation was not
necessary to achieve ring-closure.
Synthesis of Macrocyclic Neoglycoconjugate
An additional class of carbohydrate-containing macrocycles whose syntheses were
achieved using RCM are neoglycoconjugates. Dondoni and Marra synthesized these
neoglycoconjugate analogs beginning with oligosaccharides 1.64a-c. Treatment with pentenyl
bromide and NaH in DMF gave the corresponding dialkenyl RCM precursors. RCM facilitated
by Grubbs second generation catalyst in carbon tetrachloride followed by alkene reduction gave
the desired macrocyclic compounds. Debenzylation and subsequent acetylation afforded the final
compounds 1.66 – 1.68. Various other macrocyclic neoglycoconjugates were synthesized by
Kirschning41, Westermann42, Krausz43, Danishefsky44, and Len45, all employing RCM to
complete their various syntheses.
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Scheme 1-15. Dondoni and Marra Synthesis of Neoglycoconjugates
Ipomoeassins
The ipomoeassins are a family of resin glycosides isolated from the leaves of Ipomoea
squamosa Choisy from the Suriname rainforest. Initially, five compounds were isolated and
characterized by David Kingston and colleagues in 2005, ipomoeassins A-E46. In 2007, one
fraction from the previous isolation work was re-examined and discovered to contain an
additional compound, ipomoeassin F, with a different retention time on HPLC47. Much interest
was shown in the originally isolated ipomoeassins A-E due to their high cytotoxicity against the
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A2780 ovarian cancer cell line. Later, when ipomoeassin F was isolated, it was shown to have
IC50 values around 14 times more potent than ipomoeassin A, even though the only structural
difference between the two compounds is two methylene units in the aglycon48. Structurally, the
ipomoeassins consist of a fucose and glucose-derived (1→2)-β-disaccharide joined at O-1’ and
O-6’’ by a 14 or 16 carbon fatty-acid-derived chain, forming a macrocyclic structure. The
ipomoeassins vary in three different positions (Figure 1-2), one being acylation of the C-4
hydroxyl group of the
fucosyl moiety. The other
differences are found on
the aglycon where C-5
can have an acetyl group,
hydroxyl group, or no

Figure 1-2. General Structure of Ipomoeassins A-F

substituent, and the length of the aglycon can be 14 or 16 carbons. These small changes can have
a drastic impact on the potency of the compound as seen with the difference in activity between
ipomoeassin F and A.

Table 1-1. Cell Growth Inhibition Data for Naural Ipomoeassins A-F
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Synthesis of the Ipomoeassins
Prior to the work by the Shi group, two different methodologies across three publications
existed on the synthesis of the ipomoeassin family, both relying on a key RCM for construction
of the macrocycle. The first of these publications came in 2007, by Fürstner et al. They reported
the first total synthesis of ipomoeassin B and E49. Two years later, in 2009 they published the
total synthesis of all the ipomoeassins, A-F50, employing a flexible synthetic route that could
give them access to all members of the family. In the Fürstner work, they relied on a
multitasking C-silylation strategy to create a surrogate for the cinnamic acid moiety, allowing
them to introduce this unsaturated group at an early stage of the synthesis without it interfering
with the RCM or being unintentionally reduced during the subsequent hydrogenation50. Their
synthesis commenced with the assembly of disaccharide 1.73 followed by a selective
esterification to introduce the tiglate group followed by a TBS introduction to protect the
remaining free hydroxyl. A reductive opening of the benzylidene acetal was expected to give
compound 1.71 but was unsuccessful. Instead, compound 1.72 was obtained in a 4:1 ratio
causing them to employ the aforementioned C-silylation strategy and introduce the cinnamate
prior to RCM instead of afterwards as was initially planned. With the cinnamate installed, the
remaining portion of the aglycon could be introduced via a Yamaguchi esterification to give the
key RCM precursor 1.70. RCM followed by hydrogenation, desilylation, and acetonide removal
gave triol 1.69. The triol could then be appropriately acetylated to form ipomoeassins A, C, D, or
F or left as the hydroxyl to form ipomoeassins B or E. This route was flexible enough to allow
the synthesis of all the natural ipomoeassins by introducing the appropriate aglycons as well as
the first synthesis of 3 ipomoeassin derived analogs.
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Scheme 1-16. Retrosynthesis for the Fürstner Synthesis of the Ipomoeassins
Though the first of the ipomoeassins were synthesized by Fürstner et al., Postema and
colleagues were the first to report the synthesis of ipomoeassin F in 200948. Their approach
began with the preparation of the trichloroacetimidate glucosyl donor 1.74 and fucoside acceptor
1.75. Schmidt glycosylation conditions coupled the two monosacharride fragments and was
followed by treatment with CSA to remove the isopropylidene unit. A regioselective DCCmediated esterification gave the RCM precursor 1.77. Using the Hoveyda-Grubbs second
generation catalyst they were easily able to use RCM to form the macrocycle. Hydrogenation
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then cleanly reduced the resulting double bond and cleaved the benzyl protecting group. Since
they closed the ring prior to introduction of any other unsaturated groups, they didn’t have to be
concerned with any undesired reductions. They then selectively protected the C-3 position of
fucose using chloroacetic acid to allow for the subsequent introduction of the cinnamate moiety.
Desilylation then allowed for the installation of the tigloyl group in the pennultimate step. A final
deprotection yielded ipomoeassin F for the first time. The synthetic material proved to be
identical to the sample isolated by the Kingston group.

Scheme 1-17. Postema Synthesis of Ipomoeassin F
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SYNTHESIS OF THE C11 EPIMER OF IPOMOEASSIN F

While two groups had already published the syntheses of the ipomoeassins48–50, SAR
studies were still necessary to further interrogate the protein-drug interactions of the
ipomoeassins. Although these compounds show a high cytotoxicity towards a number of cancer
cell lines, little was known about their mode of action. In fact, the cytotoxicity profile of
ipomoeassin A had no significant COMPARE correlation with any of the recorded anticancer
agents in the National Cancer Institute (NCI)51, possibly suggesting a new potential druggable
target. SAR studies could help to reveal the pharmacophore of the ipomoeassins and eventually
lead to the development of chemicals probes for use in target identification. In later work, the Shi
group discovered Ipomoeassin F binds Sec61α52.
In order to begin the SAR studies, we first needed a flexible and scalable synthetic route
that would facilitate the synthesis and biological studies of the scarcely available natural product,
as well as its various analogs. We initially chose ipomoeassin F as our target due to its higher
potency compared to the other ipomoeassins. We also used the same route to synthesize the C11R epimer of ipomoeassin F to explore the effect of stereochemistry on the bioactivity53,54.
While most all of the resin glycosides contain a chiral center in the aglycon, interestingly, they
all have the same relative configuration. The role of this chiral center has never been explored
for not only the ipomoeassins, but for all of the resin glycosides.
Retrosynthetic Strategy
To begin planning an appropriate synthetic route for ipomoeassin F and it’s epimer, we
first carefully evaluate the two previous syntheses of this natural product 48,50. It seemed clear that
an RCM approach would be the most favorable way to construct the 20-membered macrolactone
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ring as its utility had been demonstrated in a wide variety of resin glycosides. However, as
shown by Postema and Fürstner, it is not without its challenges, primarily the unsaturated ester
functionalities decorating the disaccharide core. To circumvent these issues we chose to
introduce the cinnamoyl moiety in the penultimate step of the synthesis53, in part due to the
incompatibly with the necessary hydrogenation step, but also to enable the synthesis of various
analogs at the position. Cinnamoyl-containing compounds have received much attention in
medicinal research due to their antitumor properties55 and the α,β-unsaturated Michael system as
contained by cinnamic acid is known to function as a covalent protein modifier through
conjugate addition56. Bearing these things in mind, we anticipated that this group could play an
important role in the activity of the ipomoeassins and wanted a synthesis that could later be used
to construct analogs at this position. In later work from the Shi group, this theory was validated
as the cinnamte and tiglate were critical to the cytotoxicity57,58
From here, we envisioned constructing the RCM precursor by relying on a regioselective
esterification to introduce the unsaturated ester fragment. This would free us from having to
protect and subsequently deprotect the 4-O-Glcp position before introducing the cinnamate. We
proposed assembling the key diol intermediate from a D-glucosyl donor and a fucoside acceptor
with one aglycon fragment already installed. Appropriate protecting groups were a key
consideration for this intermediate as they would need to be stable to hydrogenation conditions
and also be removed without disturbing the other ester groups. This led us to protecting both the
3-O-Glcp and the 3-O-Fucp with TBS which could both be easily removed in the final step.
The glycosylation to form the disaccharide core would be accomplished using Schmidt
glycosylation conditions, but the requisite β-(1→2) glycosidic linkage meant there would need to
be a protecting group which could direct the glycosylation through neighboring group
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participation. We chose to use the allyloxycarbonyl (Alloc) group for this purpose because it
could be removed under mild conditions, leaving the isopropylidene protection unaltered. It

Scheme 2-1. Retrosynthetic Strategy for Ipomoeassin F and its Epimer
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would later have to be exchanged for a TBS group due to incompatibility with the
RCM/hydrogenation step. The tiglate could be installed prior to RCM/hydrogenation as Fürstner
previously demonstrated a trisubstituted olefin would not be reduced if Wilkinson’s catalyst was
used for hydrogenation. After a deprotection to form the glucosyl hemiacetal, the
trichloroacetimidate donor could be formed for coupling with the fucoside acceptor. An
appropriately protected fucoside acceptor could be generated from a glycosylation with a
peracetylated fucosyl donor and non-1-en-4-ol. This would introduce one half of the aglycon and
install the desired stereochemistry for both ipomoeassin F and it’s epimer.
Synthesis of the Aglycon for the 11R-Epimer of Ipomoeassin F
As previously mentioned, it is known that the aglycon of the ipomoeassins can drastically
impact the bioactivity of the compounds, as seen with ipomoeassin A and F. There are various
changes to this region that could potentially be explored, but the first obvious modification was
changing the configuration of the sole stereocenter. The planned synthetic route sets the
configuration of the chiral center early in synthesis by using commercially available R or Sepichlorohydrin. In order to synthesize the epimer of ipomoeassin F it would be necessary to
start from the beginning of the synthesis.
The aglycon in its entirety consists of 16 carbons. However, it would be assembled as
two fragments. One fragment (highlighted red in Scheme 2-2), (4R)-non-1-en-4-ol would be
coupled via glycosylation to a fucosyl donor while the other (highlighted blue in Scheme 2-2), 4oxo-8-nonenoic acid, would be attached after the formation of the disaccharide through an
esterification. The two olefin containing fragments would then be coupled using RCM.

27

Scheme 2-2. Aglycon of the 11R-Epimer of Ipomoeassin F

Preparation of (4R)-nonen-4-ol
The first portion of the aglycon to be synthesized was (4R)-nonen-4-ol as it would serve
as the acceptor for glycosylation with the peracetylated fucosyl acetimidate donor. The synthesis
relies on commercially available (4R)-epichlorohydrin as a source of the desired chirality. The
epoxide was opened up by addition of butylmagnesium bromide in the presence of copper (I)
cyanide (CuCN) to give (R)-1-chloro-2-heptanol as a single enantiomer. Treatment with an
excess of sodium hydroxide in diethyl ether would re-form the epoxide through a base-catalyzed
intramolecular SN2 reaction. An additional Grignard reaction with vinylmagnesium bromide
would open the epoxide once again to give the desired (4R)-nonen-4-ol. After completion of the
three step sequence, the final product was then purified by column chromatography to give the
final compound with a 58% yield across all three steps.
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Scheme 2-3. Synthesis of (4R)-nonen-4-ol

Preparation of 4-oxo-8-nonenoic acid
The remaining fragment of the aglycon, 4-oxo-8-nonenoic acid could be prepared on a
multi-gram scale in a single, albeit low yielding, step starting from succinic anhydride. The
succinic anhydride was opened through a Grignard reaction with pentenylmagnesium bromide in
the presence of CuCN. It was necessary to use an excess of the Grignard reagent to drive the
reaction to completion, however, the extra reagent could then add to the ketone as well,
diminishing the yield. While there are other options to synthesize this compound, practically, it
was more efficient to be able to make the compound in a single step rather than using multiple
steps.

Scheme 2-4. Synthesis of 4-oxo-8-pentenoic acid
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Synthesis of the Fucoside Acceptor
To prepare the fucoside acceptor for coupling with the glucosyl donor, we first
established a route to synthesize a fully protected fucosyl donor which would then undergo an
anomeric deprotection to form the hemiacetal, followed by the formation of the
trichloroacetimidate donor and subsequent glycosylation with aglycon fragment 2.4. A single
deprotection would then free 2-O-fucp and provide the fucoside acceptor. This route was
successfully used to synthesize the epimer of ipomoeassin F, however further investigation into
the regioselectivity of installing protecting groups on fucose during the synthesis of the natural
product ipomoeassin F inspired a much more efficient route for the synthesis of the fucoside
acceptor which was shorter, and much easier to scale up a sufficient amount of material and was
effectively used during the synthesis of both the epimer and the natural product. The new route
first prepared a peracetylated fucosyl donor which was then coupled with the aglycon fragment
2.4. While installing this fragment earlier made it necessary to synthesize a larger amount of the
chiral alcohol, it also eliminated the need to protect and deprotect the anomeric position and
ultimately shortened the total number of steps needed. The new route also relied a regioselective
protection in which TBS could be introduced with high selectivity to the 3-O-fucp position,
eliminating the need to protect any of the other positions.
Original Preparation of the Fucoside Acceptor
The first synthesis the fucoside acceptor began with the preparation of D-fucose, as did
the improved synthesis. While fucose is commercially available, it is rather expensive and as it a
starting material for the synthesis of the epimer, substantial quantities are required. A more costeffective way of obtaining the material is from the readily available and inexpensive D-galactose.
Diisopropylidene galactose is first made followed by iodination of the remaining hydroxyl
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group. Reductive dehalogenation using hydrogen gas gives the deoxy sugar. Treatment with
acetic acid cleaves the acetonide protecting groups to give D-fucose, as reported in the
literature59.

Scheme 2-5. Synthesis of D-Fucose
With D-fucose in hand, is was then globally acetylated to give peracetylated fucose.
Thioglycoside 2.13 was then prepared directly with lewis acid-catalyzed glycosylation with
thiotoluene. Deacetylation using sodium methoxide (NaOMe) gave the deprotected thioglycoside
2.14. At this point, isopropylidenation could protect the 3-O and 4-O-fucp hydroxyl groups
leaving the 2-O position open for a subsequent orthogonal protection with an allyoxycarbonyl
(Alloc) group. Cleavage of the acetonide would then allow for a regioselective TBS introduction
to the favored 3-O position and the remaining hydroxyl group was acetylated. With all of the
hydroxyl groups appropriately protected, the anomeric position was then deprotected using NBS
to give the hemiacetal 2.20. The hemiacetal was then converted to the fucosyl donor 2.21 with
trichloroacetonitrile in the presence of DBU.
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Scheme 2-6. Original Synthesis of the Fucosyl Donor
With the fully protected fucosyl donor established, it could then be coupled to the alcohol
acceptor 2.4 via standard Schmidt glycosylation conditions. The Alloc protecting group could
then be removed to furnish the fucoside acceptor to be coupled with the glucosyl donor. The
main advantage of this route was the fact the aglycon was attached in the penultimate step,
reducing the total amount of alcohol 2.4 that needed to be synthesized. Overall, this synthesis
was much too lengthy though and it was much more efficient and scalable to introduce the
aglycon earlier on do less manipulation of protecting groups.

Scheme 2-7. Original Synthesis of Fucoside Acceptor
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Updated Preparation of the Fucoside Acceptor
As mentioned, our original synthetic route was successful in preparing the desired
fucoside acceptor, but it was a very time-consuming process to scale up enough acceptor to
complete a total synthesis. One way we addressed this problem was to introduce the aglycon
early in the synthesis. With the aglycon already in place, there is one less hydroxyl group to
protect and deprotect. Our synthesis still began with preparation of peracetylated D-fucose 2.12,
but afterwards we performed an anomeric deacylation with benzylamine (BnNH2) to give the
fucose hemiacetal which was converted to the fucosyl donor 2.25.

Scheme 2-8. Updated Synthesis of Fucosyl Donor
At this point, a glycosylation coupled the donor and aglycon acceptor to furnish fucoside
2.26. A global deacylation then gave triol 2.27. We then greatly shortened the synthesis by
exploiting the difference in reactivity of the three hydroxyl groups. The reactivity of secondary
hydroxyl groups in the galacto configuration had been previously established in the literature60 as
3-OH > 2-OH > 4-OH. We anticipated this trend would hold true with 6-deoxy galactopyranose
(D-fucose) as well and the 3-OH would be the most nucleophilic due to hydrogen bonding with
the axial 4-OH. To our delight, we obtained regioselective silylation at the 3-OH position of the
triol in good yield (71%). We followed this trend in regioselectivity and assumed we could
directly use diol 2.28 as the fucoside acceptor for a regioselective glycosylation at the more
reactive equatorial 2-OH position of fucose without having to first protect the 4-OH.
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Scheme 2-9. Updated Synthesis of Fucoside Acceptor
Synthesis of the Glucosyl Donor
With the successful completion of the fucoside acceptor, we then turned our attention to
its coupling partner, the glucosyl donor. Before the glycosylation, we sought to already have the
tiglate group established at the 3-OH position and have the remaining hydroxyl groups
appropriately protected as well as a 2-OH protecting group that would serve as a directing group
for the glycosylation through neighboring group participation so that we could form the requisite
β-glycosidic linkage. With these requirements in mind we planned glucosyl donor 2.37. The
synthesis commenced with peracetylated D-glucopyranose. It is known for β-Dglucopyranosides that esterification reactions favor the 3-OH position over the 2-OH position60,
so we first synthesized p-methoxyphenyl (PMP)- β-D-glucopyranoside to try to exploit this
difference in reactivity
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Scheme 2-10. Synthesis of the Glucosyl Donor
To make the PMP-glucoside 2.30, the peracetylated glucose was reacted with 4methoxylphenol in the presence of a Lewis acid and stirred for six hours at ambient temperature.
The acetyl groups were then removed using sodium methoxide in methanol. The 4-OH and 6-OH
positions could then be protected by isopropylidenation. At this point, a Steglich esterification
could be attempted to try to regioselectively install the tiglate at the 3-OH position relying on the
reactivity trend mentioned above. To our dismay, we found that the reaction favored the 2-OH
position in a ratio of 2.4:1. Since esterification reactions should favor the 2-OH position in α-Dglucopyranosides60, we turned our attention to making the α-anomer of the previously mentioned
compound. To synthesize this molecule, we followed the same reaction sequence but by relying
on the anomeric effect and leaving the glycosylation for four days at an elevated temperature, we
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were able to obtain the anomer. Using compound 2.34, we now tried to regioselectively install
the Alloc protecting group at the 2-OH position and much to our delight, found that we
exclusively obtained the desired regioisomer. We chose the Alloc group for this position due to
the fact that it should direct our glycosylation to the desired anomer and could be removed under
mild conditions. Acylation of the remaining 3-OH with tiglic acid successfully yielded the
glucosyl donor precursor 2.36. Cleavage of the PMP group in a solution of ceric ammonium
nitrate (CAN) gave the hemiacetal which was subsequently converted to the trichloroacetimidate
donor 2.37 upon treatment with trichloroacetonitrile and DBU.
Completion of C11 Epimer Synthesis
With all of the fragments complete, the disaccharide intermediate could finally be
prepared. Fucoside 2.28 and glucosyl donor 2.37 were coupled by a regio- and stereoselective
glycosylation to exclusively form the key β-(1 → 2)-linked disaccharide intermediate 2.38, as
confirmed by 1H, COSY, and HSQC NMR spectra. The 4-O-fucp acetyl group was then installed
followed by deisopropylidenation with camphorsulfonic acid (CSA) in methanol. The Alloc
group could then be removed and regioselectively replaced with TBS which would be
undisturbed by the RCM/hydrogenation step.
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Scheme 2-11. Synthesis of Disaccharide Intermediate
After completion of key disaccharide intermediate 2.40, the remaining portion of the
aglycon was regioselectively introduced to the 6-O-glcp position via Steglich esterification to
form the RCM precursor 2.41. RCM with Hoveyda-Grubbs second generation catalyst was then
used to smoothly close the ring.

Scheme 2-12. Synthesis of Ring-Closed Intermediate
To complete the synthesis of the epimer, the resulting olefin from the RCM step was
reduced using hydrogenation with Wilkinson’s catalyst leaving the unsaturated tiglate moiety
intact. Then, in the penultimate step, cinnamate was introduced followed by a final deprotection
in 1M TBAF in THF to yield, for the first time, the 11R-epimer of ipomoeassin F over 17 steps
of the longest linear sequence, from commercially available starting materials.
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Scheme 2-13. Completion of the 11R-Epimer of Ipomoeassin F
Cytotoxicity of the 11R-Epimer of Ipomoeassin F
After synthesizing the 11R-epimer of ipomoeassin F, the cytotoxicity was evaluated
across a number of cancer cell lines in an effort to determine the role the stereochemistry of the
aglycon plays in ipomoeassin F’s biological activity. The cytotoxicity was obtained by using the
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric assay with
Taxol as the positive control. The results were compared with those obtained from the synthetic
sample of ipomoeassin F. The cytotoxicity was evaluated against a total of seven cell lines. Five
of these (MDA-MB-231, MCF7, HeLa, U937, and Jurkat) are human tumor cell lines, one was
an immortalized normal human mammary epithelial cell line (MCF-10A) and the last one was an
immortalized normal mouse embryo fibroblast cell line. Table 2-1 below summarizes the results
of the assay, showing the concentrations required for 50% cell death (IC50 values) when
compared to the vehicle-treated negative control (IC50 values). Although the 11R epimer was still
quite toxic to the cells, it was significantly (20-80 fold) less potent than ipomoeassin F in its
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native configuration, illustrating the importance of the molecule’s overall conformation to its
biological activity.

Table 2-1. Cell Cytotoxicity of Ipm F and Epimer

Experimental Procedures
Reactions were carried out in oven-dried glassware. All reagents were purchased from
commercial sources and were used without further purification unless specified. Except stated
otherwise, all reactions were carried out under a nitrogen atmosphere and monitored by thin
layer chromatography (TLC) using Silica Gel GF254 plates (Agela) with detection by charring
with 5% (v/v) H2SO4 in EtOH or by visualizing in UV light (254 nm). Column chromatography
was performed on silica gel (230–450 mesh, Sorbent). The ratio between silica gel and crude
product ranged from 100 to 50:1 (w/w). NMR data were collected on a Bruker 300 or 400 MHz
NMR spectrometer and a Bruker 300 or 400 MHz system. 1H NMR spectra were obtained in
deuterochloroform (CDCl3) with chloroform (CHCl3, δH = 7.27 for 1H) as an internal reference.
13C NMR spectra were proton decoupled and were in CDCl3 with CHCl3 (δC = 77.0 for 13C)
as an internal reference. Chemical shifts are reported in ppm (δ). Data are presented in the form:
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chemical shift (multiplicity, coupling constants, and integration). 1H data are reported as though
they were first order. The errors between the coupling constants for two coupled protons were
less than 0.5 Hz, and the average number was reported. Proton assignments, when made, were
done so with the aid of COSY NMR spectra. For some compounds, HSQC and HMBC NMR
were also applied to assign the proton signals. Optical rotations were measured on an Autopol
III Automatic Polarimeter at 25 ± 1 oC for solutions in a 1.0 dm cell. High resolution mass
spectrum (HRMS) and were acquired in the ESI mode.

Synthesis of the Epimer Aglycon
Preparation of (4R)-non-1-en-4-ol

(2R)-1-chloro-2-heptanol 2.2. A mixture of Mg (4.08 g, 144.4 mmol), catalytic I2 and dry
THF (120 mL) were heated to reflux (68-70 oC). While heating, 0.5 mL of bromobutane was
added to the mixture. One the refluxing temperature was reached, the remaining bromobutane
(17.4 mL, 144.4 mmol) was added dropwise to the mixture under a nitrogen atmosphere. After
all the Mg had been consumed to form the Grignard reagent the solution was cooled to RT. The
butyl magnesium bromide was added using an addition funnel to a solution of (R)epichlorohydrin 2.1 (10.16 g, 130.3 mmol) and CuCN (1.17 g, 116.0 mmol) at -78 oC over 1 hr.
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The reaction was slowly warmed to -20 oC over 3-4 hrs. The reaction was quenched with sat. aq.
NH4Cl (200 mL) and the solvent removed under reduced pressure. The organic layer was
extracted with Et2O (250 mL x 2), dried over Na2SO4, filtered, and solvent carefully removed
under reduced pressure. Compound 2.2 was taken to the next step without further purification.
1

H NMR (300 MHz, CDCl3) δH 3.80 (m, 1H, 2 CH), 3.49 (dd, J = 6.12 Hz, 1H Cl-CH2), 2.27 (m,

1H), 1.52 (m, 2H), 1.31 (m, 6H), 0.89 (t, J = 6 Hz, 3H, ‒CH3).

13

C NMR (CDCl3, 75 MHz) δC

71.5 (‒CH2), 50.6 (‒CH2), 34.3 (‒CH2), 31.7 (‒CH2), 25.2 (‒CH2), 22.6 (‒CH2), 14.0 (‒CH3).61

2-pentyl-(2R)-oxirane 2.3. NaOH (36.0 g, 361.2 mmol) was added to a solution of the
crude α-chloro alcohol 2.2 (18.14 g, 120.4 mmol) at RT and allowed stirred for 4-5 hrs. The
reaction was monitored by TLC (silica, Hex-EtOAc 4:1, Rf = 0.74). Upon completion the
reaction was poured into ice water and extracted with Et2O (200 mL x 3). The organic layers
were combined, dried over Na2SO4, filtered, and the Et2O was removed under reduced pressure.
The epoxide 2.3 was used directly in the next step without further purification. 1H NMR
(CDCl3, 400 MHz) δH 2.94–2.88 (m, 1 H), 2.75 (dd, J = 5.0, 4.0, Hz, 1H), 2.46 (dd, J = 5.0, 2.8
Hz, 1H), 1.56–1.28 (m, 8H), 0.90 (m, 3H, ‒CH3).13C NMR (100 MHz, CDCl3) δC 195.6 (O‒C‒
O), 64.2 (O‒CH2), 32.2(‒CH2), 31.3 (‒CH2), 25.4 (‒CH2), 22.6 (‒CH2), 14.1 (‒CH3).62,63

(4R)-nonen-4-ol 2.4. Vinylmagnesium bromide (175 mL, 109.4 mmol, 0.7 M in THF)
was added dropwise at -78 oC to a solution of the crude epoxide 2.3 (9.61 g, 66.6 mmol), CuCN
(845 mg, 66.6 mmol), and dry THF (200 mL). The reaction was kept at -78 oC for 0.5 hrs and
slowly warmed to 0 oC over 3-4 hrs. The reaction was quenched with sat. aq. NH4Cl (150 mL)
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and the THF removed under reduce pressure. The organic layer was extracted with Et2O (225
mL x 3) and the combined organic layers were washed with brine (200 mL). The organic layer
was dried over Na2SO4, filtered, and solvent removed under reduced pressure. The oil was
purified by column chromatography (silica, Hex-EtOAc, 10:1 → 6:1) to give the alcohol 2.4 in
64% (12.12 g) from (R)-epichlorohydrin. 1H NMR (300 MHz, CDCl3) δH 5.84 (dd, J =17.2,
10.2, 7.1 Hz, 1H, HC=), 5.19–5.09 (m, 2H, =CH2), 3.65 (br, s, 1H, C‒OH), 2.37–2.25 (m, 1H,
HC‒O), 2.20–2.07 (m, 2H), 1.67–1.56 (m, 2H), 1.53–1.21(m, 8H), 0.89 (t, J = 6.6 Hz, 3H, ‒
CH3).

13

C NMR δC (75 MHz, CDCl3) δC 134.9 (=CH), 118.0 (H2C=), 70.7 (C‒H), 41.9 (‒CH2),

36.8 (‒CH2), 31.8 (‒CH2), 25.3 (‒CH2), 22.6 (‒CH2), 14.0 (‒CH3).64–66

Preparation of 4-oxo-8-nonenoic acid

4-oxo-8-nonenoic acid 2.6. Mg (1.64 g, 6.8 mmol), I2 (trace), and 5-bromopentene X
(few drops, initiate the Grignard reaction) dry THF (100 mL) were combined, then heated to
reflux under a N2 atmosphere. Then 5-bromopentene 2.5 (8.1 mL, 67.1 mmol) was added to the
reaction mixture dropwise over 30 mins and continued to heat at reflux for 2 hrs (trace amount of
Mg). The Grignard reagent was cooled to RT, while a solution of succinic anhydride (7.35 g,
73.8 mmol) in THF (60 mL) was cooled to 0oC. After cooling to RT, the Grignard reagent was
added dropwise (1 hr.) to the succinic anhydride and THF, then slowly warmed to RT overnight.
TLC showed the reaction complete (Hex:EtOAc:AcOH, 79.5:20:0.5). 1 M HCl (75 mL)
quenched the reaction and the mixture was stirred for 10 mins. The THF was then removed
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under reduced pressure. The aqueous layer was extracted with DCM (75 mL x 2) then acidified
with conc. HCl to a pH of 2-3. The aqueous layer was extracted with DCM (40 mL x 3). The
combined organic layers were dried over Na2SO4, filtered, and concentrated to dryness under
reduced pressure. Purification by column chromatography gave the acid 2.6 in 32% yield (silica,
Hex–EtOAc–AcOH 100:0:0→75:25:0.5). 1H NMR (400 MHz, CDCl3) δH 5.81-5.71 (m, 1H),
5.04-4.97 (m, 2H), 2.72 (t, 2H, J = 6.4 Hz), 2.63 (t, 2H, J = 6.4 Hz), 2.46 (t, 2H, J = 7.2), 2.05 (t,
2H, J = 6.0 Hz), 1.70 (app. qui., 2H).

13

C NMR (100 MHz, CDCl3) δC 208.7 (C=O), 178.1,

137.8 (C=C), 115.9 (C=C), 41.7, 36.8, 32.9, 27.7, 24.7. 67,68
Synthesis of the Fucoside Acceptor
Preparation of D-Fucose

1,2:3,4-bis-O-(1-methylethylidene)-6-deoxy-6-iodo-α-D-galactopyranose 2.9. To a 1L
RBF was added toluene (500 mL) and diisopropylidene-galactose 2.8 (52.28 g, 200.8 mmol),
PPh3 (63.21 g, 241.0 mmol), and imidazole (49.22 g, 723.1 mmol) at RT. Then I2 (63.21 g,
241.0 mmol) was added to the reaction mixture and allowed to stir at 80 oC overnight as the
reaction turned a dark brown color. After completion of the reaction (silica, Hex-EtOAc 2:1, Rf =
0.76), the reaction mixture was quenched with MeOH (10 mL) and the resulting solution was
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concentrated to a residue. The reaction mixture was filtered through a pad of Celite and a sat. aq.
solution of Na2S2O3 was added until the slurry turned almost clear (yellow). The aqueous layer
was extracted with DCM (400 mL x 2), dried over Na2SO4, and the solvent evaporated under
reduced pressure. The syrup was purified by column chromatography (silica, Hex-EtOAc
5:1→3:1) to give 2.9 in 70% (52.47 g). 1H NMR (CDCl3, 400 MHz) δH 5.54 (d, J = 5.1 Hz, 1H,
1-H-Glcp), 4.61 (dd, J = 7.9, 2.5 Hz, 1H), 4.41 (dd, J = 7.9, 1.8 Hz, 1H), 4.30 (dd, J = 5.1, 2.5
Hz, 1H), 3.95 (td, J = 7.0, 1.8 Hz, 1H), 3.32 (dd, J = 10.1, 6.9 Hz, 1H), 3.20 (dd, J = 10.1, 7.2
Hz, 1H), 1.55 (s, 3H, ‒CH3), 1.45 (s, 3H, ‒CH3), 1.36 (s, 3H, ‒CH3), 1.37 (s, 3H, ‒CH3), 1.33 (s,
3H, ‒CH3); 13C NMR (CDCl3, 100 MHz) δC 109.6 (O‒C‒O), 108.8 (O‒C‒O), 96.8 (C-1), 71.7,
71.1, 70.6, 69.1, 26.1 (‒CH3), 26.0 (‒CH3), 25.1 (‒CH3), 24.6 (‒CH3).69,70

1,2:3,4-bis-O-(1-methylethylidene)-6-deoxy-α-D-galactopyranose 2.10. Pd/C (10 g) was
added to a solution of the iodo intermediate 2.9 (31.23 g, 84.3 mmol), DIEA (21.9 mL, 126.5
mmol), and MeOH (150 mL). Under a H2 atmosphere, the pressure was increased to 80 pounds
per square inch (PSI) and allowed to shake at RT overnight (Parr shaker). TLC (silica, HexEtOAc 2:1) showed the reaction was complete and the reaction was quenched with NEt3 and
filtered through a pad of Celite. The crude product 2.10 was used directly in the next step
without further purification. 1H NMR (400 MHz, CDCl3) δH 5.57 (d, J = 5.2 Hz, 1H, H-1-Fucp),
5.48 (dd, J = 8.1 Hz, 2.8 Hz, 1H, H-3-Fucp), 4.26 (dd, J = 5.3 Hz, 2.4 Hz, 1H, H-2-Fucp), 4.06
(dd, J = 1.6 Hz, 8.0 Hz, 1H, H-4-Fucp), 3.89 (ddd, 1H, H-5-Fucp), 1.50 (s, 3H, ‒CH3), 1.44 (s,
3H, ‒CH3), 1.33 (s, 3H, ‒CH3), 1.30 (s, 3H, ‒CH3), 1.23 (d, J = 6.4 Hz, 3H, ‒CH3). 13C NMR
(75 MHz, CDCl3) δC 109.0, 108.3, 96.6, 73.5, 70.9, 70.4, 63.5, 26.0 • 2, 24.9, 24.4, 15.9. 71,72
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6-deoxy-α,β-D-galactopyranose 2.11. The crude intermediate 2.10 (44 g) was dissolved
in 80% acetic acid (400 mL) and heated to reflux (125 oC). The reaction was allowed to reflux
overnight at which point TLC (silica, Hex-EtOAc 6:1, Rf = 0.11) indicated the reaction was
finished. The reaction was cooled to RT, then co-evaporated with toluene (200 mL x 3). The
slurry was diluted with sat. aq. NaHCO3 (300 mL) and extracted with DCM (300 mL ∙ 3). The
combined organic layers were dried over Na2SO4, filtered, and concentrated to dryness. The
crude D-Fucp 2.11 was used directly in the next step without further purification. 1H NMR (400
MHz, D2O) δH 5.05 (d, J = 3.8 Hz, 1H, 1-H-Fucp), 4.41 (d, J = 7.9 Hz, 1H, H-1-Fucp), 4.06 (q, J
= 6.7 Hz, 1H, H-5-Fucp), 3.74-3.64 (m, 4H, H-2-Fucp, H-3-Fucp, H-4-Fucp, H-5-Fucp), 3.59 (d,
J = 2.8, 4-OH-Fucp), 3.50 (dd, J = 10.1 Hz, 3.4 Hz, 3-OH-Fucp), 3.31 (dd, J = 10.1 Hz, 7.9 Hz,
2-OH-Fucp), 1.10 (d, J = 6.3 Hz, 3H, H-6-Fucp), 1.07 (d, J = 6.4 Hz, 3H, H-6-Fucp).73,74

1,2,3,4-O-tetracetate-6-deoxy-α,β-D-galactopyranose 2.12. The crude D-Fucp 2.11 (32.1
g, 195 mmol) was dissolved in acetic anhydride (75 mL) and pyridine (140 mL) and cat. DMAP
was added. The reaction was allowed to stir at RT overnight, while turning a deep orange color.
TLC (silica, Hex-EtOAc 2:1, Rf = 0.61) showed the reaction to be complete and the solution was
co-evaporated with toluene (200 x 3). To the residue was added sat. aq. NaHCO3 (300 mL)
which was extracted with DCM (300 mL x 3). The combined organic layers were dried over
Na2SO4, filtered, and solvent removed under reduce pressure. The residue was purified by
column chromatography (silica, Hex-EtOAc, 4:1→3:1) to the peracetylated D-Fucp 2.12 in 48%
yield over three steps from 2.9. 1H NMR (400 MHz, CDCl3) δH 6.30 (d, J = 3.0 Hz, 1H), 5.65
(d, J = 8.5 Hz, 1H), 5.30-5.23 (m, 5H), 5.05 (dd, J = 10.5, 3.5 Hz, 1H), 4.24 (q, J = 6.5 Hz, 1H),
3.93 (q, J = 6.5 Hz, 1H), 2.15-1.95 (series of s, 3H, ‒CH3), 1.19 (d, J = 6.5 Hz, 3H, ‒CH3), 1.12
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(d, J = 6.5 Hz, 3H, ‒CH3). 13C NMR (100 MHz, CDCl3) δC 170.48, 170.46, 170.11, 169.94,
169.90, 169.4, 169.1, 166.4, 92.2, 89.9, 71.3, 70.6, 70.3, 70.0, 68.0, 67.9, 67.3, 66.5, 22.1, 20.9,
20.8, 20.63, 20.60, 20.57, 20.53, 15.92, 15.91. 75–77

Preparation of the Fucosyl Donor

2,3,4-O-triacetate-6-deoxy-α,β-D-galactopyranose 2.24. The peracetylated D-Fucp 2.12
(10.55 g, 31.7 mmol) was dissolved in dry THF (150 mL) and BnNH2 (4.6 mL, 47.6 mmol). The
reaction was stirred at RT overnight at which point TLC showed the reaction to be complete
(silica, Hex-EtOAc 1:1, Rf = 0.54, 0.49). The THF was removed under reduced pressure, the
residue diluted with DCM (200 mL), washed with 5% HCl, then sat. aq. NaHCO3. The organic
layer was collected, dried over NaSO4, filtered, and concentrated to dryness. The syrup was
purified by column chromatography (silica, Hex-EtOAc, 2:1→1:2) to give the α,β-hemiacetal Dfucose 2.24 in 77% (7.15 g) and carried directly to the next step.78

1-(2,2,2-trichloroethanimidate)-2,3,4-triacetate-6-deoxy-α,β-D-galactopyranose 2.25.
Trichloroacetonitrile (12.8 mL, 128 mmol) and DBU (0.68 mL, 3.2 mmol) were added to a
solution of DCM (100 mL) and the hemiacetal 2.24 (9.30 g, 32.0 mmol) at RT. The reaction was
stirred at RT for 3-4 hrs, when TLC (silica, Hex-EtOAc 1:1, Rf = 0.71 and 0.77) indicated that
the starting material had been consumed. The reaction was quenched with NEt3 (0.5 mL) and the
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DCM evaporated under reduced pressure. The residue was purified by column chromatography
(silica, Hex-EtOAc, 4:1→1:1, 0.1% NEt3) to give the α,β-Schmidt donor 2.25 in 86% yield (10.6
g). 1H NMR (300 MHz, CDCl3) δH 8.64 (s, 1H), 6.59 (d, J = 3.5 Hz, 1H), 5.51-5.35 (m, 3 H),
4.43-4.37 (br q, J= 6.6 Hz, 1 H), 2.22, 2.05, and 2.04 (3 s, 3H), 1.15 (d, J = 6.6 Hz, 3 H). 13C
NMR (75 MHz, CDCl3) δC 170.4-170.0 ∙ 3, 161.1, 93.9, 77.2, 70.5, 67.9, 66.9, 67.5, 20.7-20.6 ∙
3, 15.9.79

Preparation of the Fucoside Acceptor

1-Nonen-4R-yl 2,3,4-Tri-O-acetyl-β-D-fucopyranoside 2.26. A mixture of acceptor 2.4
(1.32 g, 9.3 mmol), donor 2.25 (4.28 g, 9.8 mmol), and 4 Å molecular sieves (3 g) in anhydrous,
redistilled CH2Cl2 (120 mL) was stirred under an N2 atmosphere for 30 min and then cooled to
−10 °C. TMSOTf(168 μL, 0.95 mmol) was added to the mixture, and then the reaction mixture
was allowed to gradually warm to ambient temperature with the cold bath in place and was
stirred for 1 h. TLC (silica, 1:3 EtOAc−hexanes) indicated that the reaction was complete. The
reaction mixture was quenched with Et3N (320 μL) and filtered. The filtrate was evaporated in
vacuo to give a residue, which was purified by silica gel column chromatography (silica,
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EtOAc−hexanes, 1:7 → 1:5) to give compound 2.26 (2.80 g, 74%) as a yellowish syrup. [α]25D
+9.7 (c 1 CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.88−5.75 (m, 1H, CH2=CHCH2−), 5.25−5.13
(m, 2H, H-4-Fucp, H-2-Fucp), 5.09−4.96 (m, 3H, H-3-Fucp, CH2=CHCH2−), 4.49 (d, J = 7.6
Hz, 1H, H-1-Fucp), 3.84−3.74 (m, 1H, H-5-Fucp), 3.65−3.56 (m, 1H, −CH2CHCH2−),
2.51−2.27 (m, 2H), 2.18 (s, 3H, CH3C=O), 2.04 (s, 3H, CH3C=O), 1.99 (s, 3H, CH3C=O),
1.50−1.40 (m, 2H), 1.40−1.23 (m, 6H), 1.24 (d, J = 6.4 Hz, 3H, H-6-Fucp), 0.89 (t, J = 6.8 Hz,
3H); 13C NMR (100 MHz, CDCl3) δ 170.8, 170.3, 169.4, 134.7, 116.9, 101.2, 81.0, 71.5, 70.3,
69.3, 69.0, 39.7, 33.5, 31.9, 24.7, 22.6, 20.8, 20.7, 20.7, 16.1, 14.0. IR (film) ν = 2936, 2856,
1755, 1600, 1368, 1254, 1229, 1078; HRMS (ESI) m/z calcd for C21H34NaO8 [M + Na]+
437.2151, found 437.2148.

1-Nonen-4S-yl β-D-fucopyranoside 2.27. MeONa (80 mg, 1.48 mmol) was added in one
portion to a solution of 2.26 (2.69 g, 6.49 mmol) in MeOH (50 mL) at room temperature. The
reaction mixture was stirred at room temperature overnight. TLC (silica, 3:1 EtOAc–hexanes)
showed the reaction was complete. Neutralization of the reaction mixture with acidic ion
exchange resin (Amberlite IR-120 (H+), Alfa Aesar) and the organic phase was concentrated in
vacuo. The residue was purified by column chromatography (silica, EtOAc–hexanes, 3:1 → 5:1)
gave triol 2.27 (1.37 g, 73%) as a colorless syrup. [α]D25 +2.0° (c 1 CHCl3). 1H NMR (400 MHz,
CDCl3) δ 5.91 – 5.78 (m, 1H, CH2=CH-CH2-), 5.11 – 4.99 (m, 2H, CH2=CH-CH2-), 4.25 (d, J =
7.6 Hz, 1H, H-1-Fucp), 3.76 – 3.54 (m, 5H, H-2-Fucp, H-3-Fucp, H-4-Fucp, H-5-Fucp, -CH2CH-CH2-), 3.90 (br 1H, OH), 3.41 (br, 1H, OH), 3.24 (br, 1H, OH), 2.46 – 2.30 (m, 2H), 1.57 –
1.48 (m, 2H), 1.45 – 1.21 (m, 9H), 0.89 (d, J = 6.8 Hz, 3H, H-6-Fucp). 13C NMR (100 MHz,
CDCl3) δ 134.98, 116.75, 102.58, 79.72, 73.94, 71.68, 71.60, 70.47, 39.55, 33.52, 31.88, 24.79,
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22.55, 16.36, 14.04; IR (film) ν = 3381, 2928, 2859, 1639, 1070, 995, 912, 756; HRMS (ESI)
m/z calcd for C15H28NaO5 [M + Na]+ 311.1834, found 311.1830.

1-Nonen-4S-yl 3-O-tert-butyldimethylsilyl-β-D-fucopyranoside 2.28. To a cold (0 oC)
solution of triol 2.27 (0.36 g, 1.2 mmol) and 1H-Imidazole (0.24 g, 3.5 mmol) in DMF (15 mL)
was added t-butyldimethylsilyl chloride (0.26 g, 1.7 mmol). The reaction was stirred at 0 oC for
30 min and then was allowed to warm to ambient temperature and stirred for another 2 h. At this
point, TLC (silica, 1:9 EtOAc–hexanes) showed the reaction was complete. The reaction mixture
was diluted with ether (25 ml), washed with water (3 × 15 mL) and brine (15 mL). The aqueous
layer was extracted with ether (25 ml). The combined organic layers were dried over Na2SO4,
filtered and concentrated. The residue was purified by column chromatography (silica, EtOAc–
hexanes, 1:3 → 1:2) to afford compound 2.28 (0.36 g, 71%) as a colorless syrup. [α]D25 +7.8° (c
1 CHCl3). 1H NMR (400 MHz, CDCl3) δ 5.91 – 5.74 (m, 1H, CH2=CH-CH2-), 5.14 – 4.98 (m,
2H, CH2=CH-CH2-), 4.20 (d, J = 7.8 Hz, 1H, H-1-Fucp), 3.73 – 3.65 (m, 1H, -CH2-CH-CH2-),
3.63 (dd, J = 9.2, 3.6 Hz, 1H, H-3-Fucp), 3.59 – 3.48 (m, 3H, H-2-Fucp, H-4-Fucp, H-5-Fucp),
2.62 (br, 1H, OH), 2.38 – 2.21 (m, 2H), 2.17 (d, J = 1.6 Hz, 1H, OH), 1.67 – 1.47 (m, 2H), 1.39
– 1.22 (m, 9H), 0.96 – 0.84 (m, 12H), 0.15 (s, 3H, CH3-Si), 0.13 (s, 3H, CH3-Si). 13C NMR (100
MHz, CDCl3) δ 135.06, 117.37, 102.24, 78.88, 74.86, 72.14, 72.08, 70.00, 38.54, 34.73, 31.81,
25.75(3), 24.73, 22.56, 18.10, 16.37, 14.09, –4.42, –4.97; IR (film) ν = 3379, 2930, 2856, 1653,
1074, 997, 800, 760; HRMS (ESI) m/z calcd for C21H42NaO5Si [M + Na]+ 425.2699, found
425.2693.
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Synthesis of the Glucosyl Donor

p-Methoxyphenyl 4,6-O-isopropylidene-α-D-glucopyranoside 2.34. To a cold (0 oC)
solution of the penta-O-acetyl-β-D-glucopyranose 2.29 (70.0 g, 179 mmol) and p-methoxyphenol
(33.4 g, 269 mmol) in dry CH2Cl2 (800 mL) was added boron trifluoride diethyl etherate (111
mL, 897 mmol) over 30 min. The mixture was then heated to 35 oC and agitated for 4 days, at
the end of which time TLC (EtOAc–hexanes, 1:2) indicated that the reaction was complete. The
reaction mixture was poured into crushed ice, and the excess boron trifluoride diethyl etherate
was neutralized by the careful addition of saturated aqueous NaHCO3 solution. The organic layer
was washed with brine, dried over Na2SO4, and concentrated in vacuo to provide a yellowish
syrup. The syrup was dried under high vacuum for 2 hours before being dissolved in MeOH (500
mL). Sodium methoxide (2 g) was added to the reaction mixture and stirred at room temperature
for 2 hours. The residue was purified by column chromatography (silica, EtOAc–MeOH, 1:20 →
1:5) to afford p-methoxyphenyl α-D-glucopyranoside 2.33 (30.8 g, 60% over 2 steps) as a white
solid. To a solution of compound 2.33 (28.8 g, 101 mmol) in DMF (200 mL) containing pTsOH·H2O (0.38 g, 2.0 mmol) was added 2-methoxypropene (11.6 mL, 121 mmol) under
nitrogen atmosphere. The resulting mixture was stirred for 6 hours at room temperature until
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completion (EtOAc–hexanes, 2:1). The reaction was quenched with Et3N (0.5 mL) and then
diluted with EtOAc (400 mL), washed with water (400 mL × 3) and brine (100 mL). The
aqueous layer was extracted with EtOAc (400 mL × 2). The combined organic layers were dried
over Na2SO4 and concentrated under reduced pressure. The residue was purified by column
chromatography (silica, EtOAc–hexanes, 1:1 → 2:1) to give compound 2.34 (30.2 g, 92%) as a
white foam. [α]D25 +124.7° (c 1 CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.02 – 6.96 (m, 2H, 2 ×
ArH), 6.84 – 6.79 (m, 2H, 2 × ArH), 5.41 (d, J = 3.6 Hz, 1H, H-1), 4.00 (td, J = 9.2, 2.0 Hz, 1H),
3.88 – 3.66 (m, 7H, H-2, H-5, 2 × H-6, -OCH3), 3.61 (t, J = 8.8 Hz, 1H), 3.45 – 3.40 (m, 1H,
OH), 3.00 – 2.92 (m, 1H, OH), 1.52 (s, 3H, (CH3)2C), 1.44 (s, 3H, (CH3)2C). 13C NMR (100
MHz, CDCl3) δ 155.41, 150.17, 118.40(2), 114.63(2), 99.80, 98.62, 73.43, 72.81, 71.85, 63.99,
62.13, 55.59, 29.01, 19.08.

p-Methoxyphenyl 2-O-allyloxycarbonyl-4,6-O-isopropylidene-α-D-glucopyranoside
2.35. Compound 2.34 (20.4 g, 62.5 mmol) was dissolved in CH2Cl2 (300 mL) containing
pyridine (20 mL, 250 mmol) and DMAP (0.76 g, 6.3 mmol), then under a N2 atmosphere, allyl
chloroformate (7.3 mL, 68.8 mmol) in CH2Cl2 (50 mL) was added drop wise to the solution at –
35 °C over 30 min. Then the reaction mixture was allowed to gradually warm to 0 °C over 30
min, at the end of which time TLC (silica, 1: 2 EtOAc–hexanes) showed it was complete. Then
the reaction mixture was quenched with MeOH (0.5 mL) and washed with 1M HCl (200 mL),
saturated aqueous NaHCO3 (100 mL) and brine (100 mL). The aqueous layer was extracted with
CH2Cl2 (200 mL). The combined organic layers were dried over Na2SO4 and concentrated under
reduced pressure. The residue was purified by column chromatography (silica, EtOAc–hexanes,
1:4 → 1:3) to give compound 2.35 (22.1 g, 86%) as a white foam. [α]D25 +153.2° (c 1 CHCl3).
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1

H NMR (400 MHz, CDCl3) δ 7.01 – 6.94 (m, 2H, 2 × ArH), 6.85 – 6.77 (m, 2H, 2 × ArH), 5.96

– 5.85 (m, 1H, CH2=CH-CH2-), 5.65 (d, J = 3.6 Hz, 1H, H-1), 5.38 – 5.22 (m, 2H, CH2=CHCH2-), 4.72 (dd, J = 9.6, 3.6 Hz, 1H, H-2), 4.66 – 4.59 (m, 2H, CH2=CH-CH2-), 4.26 (t, J = 9.2
Hz, 1H, H-3), 3.92 – 3.81 (m, 2H, H-5, H-6), 3.81 – 3.74 (m, 4H, H-6, -OCH3), 3.75 – 3.64 (m,
1H, H-4), 3.04 (br, 1H, OH), 1.54 (s, 3H, (CH3)2C), 1.45 (s, 3H, (CH3)2C). 13C NMR (100 MHz,
CDCl3) δ 155.27, 154.43, 150.25, 131.07, 119.19, 118.16(2), 114.54(2), 99.97, 95.83, 76.68,
73.68, 68.92, 68.77, 63.67, 62.05, 55.57, 28.93, 19.06.

p-Methoxyphenyl 2-O-allyloxycarbonyl-3-O-tigloyl-4,6-O-isopropylidene-α-Dglucopyranoside 2.36. DCC (8.60 g, 41.7 mmol) was added in one portion to a 0 ºC CH2Cl2 (100
mL) solution of 2.35 (11.4 g, 27.8 mmol), tiglic acid (4.17 g, 41.7 mmol) and 4dimethylaminopyridine (0.34 g, 2.78 mmol). The reaction was allowed to warm to ambient
temperature and stirred overnight. At this point, TLC (silica, 1:2 EtOAc–hexanes) showed the
reaction was complete. The reaction mixture was diluted with ether (100 mL) and hexanes (50
mL), stirred for 20 minutes, then filtered thru a pad of Celite using ether (50 mL) as the eluent
and the filtrate was concentrated in vacuo. The residue was purified by column chromatography
(silica, EtOAc–hexanes, 1:6 → 1:5) to give 2.36 (13.1 g, 95%) as a colorless syrup. [α]D25
+127.9° (c 1 CHCl3). 1H NMR (400 MHz, MeOD) δ 7.05 – 6.99 (m, 2H, 2 × ArH), 6.93 – 6.83
(m, 3H, Me-CH-C(Me)-C=O, 2 × ArH), 5.94 – 5.75 (m, 1H, CH2=CH-CH2-), 5.67 (d, J = 3.6
Hz, 1H, H-1), 5.57 (t, J = 10.0 Hz, 1H, H-3), 5.29 – 5.15 (m, 2H, CH2=CH-CH2-), 4.97 (dd, J =
10.0, 3.6 Hz, 1H, H-4), 4.65 – 4.51 (m, 2H, CH2=CH-CH2-), 4.01 – 3.79 (m, 4H, H-4, H-5, 2 ×
H-6), 3.75 (s, 3H, -OCH3), 3.75 (d, J = 4.7 Hz, 3H), 1.86 – 1.78 (m, 6H, CH3-CH-C(CH3)-C=O),
1.50 (s, 3H, (CH3)2C), 1.34 (s, 3H, (CH3)2C). 13C NMR (100 MHz, MeOD) δ 168.42, 157.02,
52

155.64, 151.67, 139.55, 132.84, 129.20, 119.40(2), 118.87, 115.73(2), 101.15, 97.66, 75.89,
73.09, 70.83, 69.81, 65.65, 63.06, 56.04, 29.33, 19.38, 14.50, 12.23.
2-O-Allyloxycarbonyl-3-O-tigloyl-4,6-O-isopropylidene-α-D-glucopyranosyl
trichloroacetimidate 2.37. To a solution of compound 2.36 (10.9 g, 22.1 mmol) in acetonitrile
(120 mL) and water (30 mL) was added a solution of ceric ammonium nitrate (CAN) (24.3 g,
44.3 mmol) in water (30 mL) over 5 min at -10 oC. The mixture was stirred for 15 min at the
same temperature, at the end of which time TLC (silica, 1:2 EtOAc–hexanes) indicated that the
reaction was complete. The reaction was quenched with saturated aqueous NaHCO3 and
extracted with EtOAc (400 mL × 2). The combined organic phase was dried over Na2SO4 and
concentrated. The obtained residue was purified by column chromatography (silica, EtOAc–
hexanes, 1:4 → 1:2) to afford the desired hemiacetal. To a solution of the obtained hemiacetal in
CH2Cl2 (100 mL) was added trichloroacetonitrile (8.9 mL, 88 mmol), and 1,8diazabicyclo[5.4.0]undecene (DBU) (0.33 mL, 2.2 mmol). The mixture was stirred overnight at
room temperature and then was concentrated. The residue was purified by column
chromatography (silica, EtOAc–hexanes, 1:5 → 1:3) to afford the glucosyl donor 2.37 (6.93 g,
59% over 2 steps) as a colorless syrup. [α]D25 ° +59.6 (c 1 CHCl3). 1H NMR (400 MHz, CDCl3)
δ 8.65 (s, 1H, CNHCCl3), 6.90 – 6.83 (m, 1H, Me-CH-C(Me)-C=O), 6.57 (d, J = 4.0 Hz, 1H, H1), 5.93 – 5.76 (m, 1H, CH2=CH-CH2-), 5.61 (t, J = 9.6 Hz, 1H, H-3), 5.36 – 5.17 (m, 2H,
CH2=CH-CH2-), 5.03 (dd, J = 9.6, 4.0 Hz, 1H, H-2), 4.65 – 4.54 (m, 2H, CH2=CH-CH2-), 4.05 –
3.72 (m, 4H, H-2, H-4, H-5, 2 × H-6), 1.90 – 1.76 (m, 6H, CH3-CH-C(CH3)-C=O), 1.49 (s, 3H,
(CH3)2C), 1.41 (s, 3H, (CH3)2C). 13C NMR (100 MHz, CDCl3) δ 166.63, 161.15, 154.17, 138.02,
131.10, 128.03, 118.80, 99.95, 93.56, 73.99, 71.65, 69.01, 68.91, 66.19, 62.02, 28.82, 18.93,
14.44, 12.12.
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Completion of C11 Epimer Synthesis
Preparation of Key Disaccharide Intermediate

1-Nonen-4S-yl 2-O-allyloxycarbonyl-3-O-tigloyl-4,6-di-O-isopropylidene-β-Dglucopyranosyl-(1→2)-3-O-tert-butyldimethylsilyl-β-D-fucopyranoside 2.38. A mixture of
acceptor 2.28 (0.450 g, 1.1 mmol), donor 2.37 (0.540 g, 1.0 mmol), and 4 Å molecular sieves (1
g) in anhydrous, redistilled CH2Cl2 (20 mL) was stirred under a N2 atmosphere for 30 min and
then cooled to -60 oC. TMSOTf (38.6 µL, 0.18 mmol) was added to the mixture. Then the
reaction mixture was allowed to gradually warm to -20 oC over 1 h, at the end of which time
TLC (silica, 1:6 EtOAc–hexanes) showed it was complete. Then the reaction mixture was
quenched with Et3N and filtered. The filtrate was evaporated in vacuo to give a residue, which
was purified by silica gel column chromatography (silica, EtOAc–hexanes, 1:20 → 1:10) to give
compound 2.38 (0.510 g, 66%) as a colorless syrup. [α]D25 –3.9° (c 1 CHCl3). 1H NMR (400
MHz, CDCl3) δ 6.89 – 6.79 (m, 1H, Me-CH=C(Me)-C=O), 5.85 – 5.79 (m, 2H, 2 x CH2=CHCH2-), 5.34 – 4.99 (m, 6H, 2 × CH2=CH-CH2-, H-3-Glup, H-1-Glup), 4.72 (dd, J = 9.6, 8.0 Hz,
1H, H-2-Glup), 4.62 – 4.49 (m, 2H, CH2=CH-CH2 -O-), 4.28 (d, J = 7.6 Hz, 1H, H-1-Fucp),
3.97(dd, J = 11.2, 5.6 Hz, 1H, H-6-Glup), 3.86 – 3.67 (m, 4H, H-2-Fucp, H-3-Fucp, H-4-Glup,
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H-6-Glup), 3.68 – 3.59 (m, 1H), 3.56 – 3.47 (m, 2H), 3.31 (m, 1H, H-5-Glup), 2.37 (br, 1H,
OH), 2.36 (t, J = 6.8 Hz, 2H), 1.83 – 1.75 (m, 6H, CH3-CH-C(CH3)-C=O), 1.55 – 1.46 (m, 2H),
1.46 (s, 3H), 1.41 – 1.20 (m, 12H), 1.00 – 0.82 (m, 12H), 0.18 (s, 3H, CH3-Si), 0.11 (s, 3H, CH3Si). 13C NMR (100 MHz, CDCl3) δ 166.85, 154.19, 137.92, 135.21, 131.42, 128.05, 118.32,
116.53, 1001.12, 99.61, 99.60, 79.94, 77.21, 75.78, 75.72, 72.36, 72.26, 71.83, 69.49, 68.37,
67.15, 62.18, 39.41, 33.45, 32.26, 28.90, 25.92(3), 24.72, 22.87, 18.79, 17.97, 16.47, 14.39,
14.03, 12.06, -4.59(2).

1-Nonen-4S-yl 2-O-allyloxycarbonyl-3-O-tigloyl-4,6-di-O-isopropylidene-β-Dglucopyranosyl-(1→2)-4-O-acetyl-3-O-tert-butyldimethylsilyl-β-D-fucopyranoside 2.39. To a
cold (0 oC) solution of compound 2.38 (392.2 mg, 0.509 mmol) and DMAP (6.2 mg, 0.051
mmol) in pyridine (3 mL) was added acetic anhydride (1 mL). The reaction mixture was heated
to 60 oC and stirred for an additional 24 h, at the end of which time TLC (silica, 1:6 EtOAc–
hexanes) indicated that the reaction was complete. The mixture was concentrated under
diminished pressure and then co-evaporated with toluene (2 × 20 mL) to give the crude product.
The residue was purified by column chromatography (silica, EtOAc–hexanes, 1:20 → 1:10) to
afford compound 2.39a (321.2 mg, 78%,) as a colorless syrup. [α]D25 –0.6° (c 1 CHCl3). 1H
NMR (400 MHz, CDCl3) δ 6.89 – 6.80 (m, 1H, Me-CH=C(Me)-C=O), 5.91 – 5.78 (m, 2H, 2 x
CH2=CH-CH2-), 5.33 – 5.02 (m, 6H, 2 × CH2=CH-CH2-, H-3-Glup, H-1-Glup), 5.00 (m, 1H, H4-Fucp), 4.74 (dd, J = 9.6, 8.0 Hz, 1H, H-2-Glup), 4.62 – 4.47 (m, 2H, CH2=CH-CH2-O-), 4.30
(d, J = 7.6 Hz, 1H, H-1-Fucp), 4.01 (dd, J = 10.8, 5.2 Hz, 1H, H-6-Glup), 3.92 (dd, J = 9.2, 8.0
Hz, 1H, H-2-Fucp), 3.80 – 3.67 (m, 3H, H-3-Fucp, H-4-Glup, H-6-Glup), 3.66 – 3.57 (m 2H),
3.31 (m, 1H, H-5-Glup), 2.35 (br, 2H), 2.11 (s, 3H, CH3-C=O), 1.82 – 1.72 (m, 6H, CH3-CH55

C(CH3)-C=O), 1.62 – 1.48 (m, 2H), 1.43 (s, 3H, (CH3)2C), 1.41 – 1.25 (m, 9H), 1.13 (d, J = 6.4
Hz, 3H, H-6-Fucp), 0.98 – 0.82 (m, 12H), 0.12 (s, 3H, CH3-Si), 0.09 (s, 3H, CH3-Si). 13C NMR
(100 MHz, CDCl3) δ 170.80, 166.81, 154.25, 137.93, 135.01, 131.43, 128.04, 118.26, 116.73,
101.56, 99.62, 99.50, 81.02, 77.10, 75.18, 73.54, 73.41, 72.23, 71.96, 68.86, 68.35, 67.20, 62.26,
39.42, 33.66, 32.30, 28.91, 25.82(3), 24.88, 22.91, 20.94, 18.80, 17.71, 16.60, 14.39, 14.23,
12.00, -4.22, -4.95.

1-Nonen-4S-yl 3-O-tigloyl-4,6-di-O-isopropylidene-β-D-glucopyranosyl-(1→2)-4-Oacetyl-3-O-tert-butyldimethylsilyl-β-D-fucopyranoside 2.39b. To a cooled (-10 oC) solution of
compound 2.39a (449.8 mg, 0.55 mmol) in 1:1 MeOH–THF (15 mL) was added CH3COONH4
(426.8 mg, 5.53 mmol). With vigorous stirring, Pd[P(C6H5)3]4 (25.6 mg, 0.02 mmol), and NaBH4
(31.2 mg, 0.82 mmol) was added in 3 portions immediately one after another. Four minutes after
the addition of the second portion of NaBH4, TLC (EtOAc–hexanes, 1:6) indicated that the
reaction was complete. The reaction mixture was concentrated under diminished pressure, the
residue was dissolved in CH2Cl2 (20 mL) and washed with water (10 mL), then the organic layer
was dried over Na2SO4. Evaporation and purification by column chromatography (silica,
EtOAc–hexanes, 1:10) afforded compound 2.39b (343.2 mg, 85%). [α]D25 –1.5° (c 1 CHCl3). 1H
NMR (400 MHz, CDCl3) δ 6.90 – 6.80 (m, 1H, Me-CH=C(Me)-C=O), 5.93 – 5.79 (m, 1H,
CH2=CH-CH2-), 5.15 (t, J = 9.6 Hz, 1H, H-3-Glup), 5.10 – 5.00 (m, 3H, CH2=CH-CH2-, H-4Fucp), 4.70 (d, J = 8.0 Hz, 1H, H-1-Glup), 4.39 (d, J = 7.6 Hz, 1H, H-1-Fucp), 3.99 – 3.85 (m,
2H, H-6-Glup, H-2-Fucp), 3.83 – 3.72 (m, 2H, H-6-Glup, H-3-Fucp), 3.72 – 3.69 (m, 2H, H-4Glup), 3.62 – 3.58 (m, 1H, H-5-Fucp), 3.57 – 3.43 (m, 2H, H-2-Glup, OH), 3.40 – 3.35 (m, 1H,
H-5-Glup), 2.49 – 2.30 (m, 2H), 2.10 (s, 3H, CH3-C=O), 1.90 – 1.73 (m, 6H, CH3-CH-C(CH3)56

C=O), 1.60 – 1.50 (m, 2H), 1.46 (s, 3H, (CH3)2C), 1.41 – 1.21 (m, 9H), 1.15 (d, J = 6.4 Hz, 3H,
H-6-Fucp), 0.94 – 0.80 (m, 12H), 0.18 (s, 3H, CH3-Si), 0.15 (s, 3H, CH3-Si). 13C NMR (75 MHz,
CDCl3) δ 170.85, 167.63, 137.40, 134.55, 128.40, 116.99, 104.48, 101.49, 99.61, 79.48, 78.80,
75.38, 72.83, 72.77, 72.68, 71.67, 68.80, 68.25, 62.26, 38.73, 32.91, 32.12, 28.96, 25.79(3),
24.66, 22.64, 20.92, 18.91, 17.82, 16.50, 14.37, 14.11, 12.12, -4.49, -4.52.

1-Nonen-4S-yl 3-O-tigloyl-2-O-tert-butyldimethylsilyl-4,6-di-O-isopropylidene-β-Dglucopyranosyl-(1→2)-4-O-acetyl-3-O-tert-butyldimethylsilyl-β-D-fucopyranoside 2.39c.
TBSOTf (0.43 mL, 1.9 mmol) was added to a solution of compound 2.39b (343.2 mg, 0.47
mmol) and 2,6-lutidine (0.55 mL, 4.7 mmol) in distilled CH2Cl2 (5 mL) at 0 oC. The reaction was
allowed to warm to ambient temperature and stirred for 24 h. At this point, TLC (silica, 1:6
EtOAc–hexanes) showed the reaction was complete. Evaporation of the solvent followed by
purification of the residue by flash chromatography (silica, EtOAc–hexanes, 1:20 → 1:10) gave
compound 2.39c (298.4 mg, 75%) as a colorless syrup. [α]D25 –6.0° (c 1 CHCl3). 1H NMR (400
MHz, CDCl3) δ 6.89 – 6.79 (m, 1H, Me-CH=C(Me)-C=O), 5.92 – 5.80 (m, 1H, CH2=CH-CH2-),
5.14 – 5.01 (m, 3H, H-3-Glup, CH2=CH-CH2 -), 5.00 – 4.91 (m, 2H, H-1-Glup, H-4-Fucp), 4.32
(d, J = 7.6 Hz, 1H, H-1-Fucp), 4.04 (dd, J = 9.2, 7.6 Hz, 1H, H-2-Fucp), 3.95 (dd, J = 10.8, 5.2
Hz, 1H, H-6-Glup), 3.85 (dd, J = 9.2, 4.0 Hz, 1H, H-3-Fucp), 3.72 (t, J = 10.4 Hz, 1H, H-6Glup), 3.69 – 3.58 (m, 2H, H-5-Fucp, -CH2-CH-CH2-), 3.57 – 3.50 (m, 2H, H-2-Glup, H-4Glup), 3.30 – 3.21 (m, 1H, H-5-Glup), 2.35 (t, J = 6.4 Hz, 2H), 2.11 (s, 3H, CH3-C=O), 1.87 –
1.75 (m, 6H, CH3-CH-C(CH3)-C=O), 1.61 – 1.46 (m, 2H), 1.45 (s, 3H, (CH3)2C), 1.40 – 1.21 (m,
9H), 1.12 (d, J = 6.4 Hz, 3H, H-6-Fucp), 1.00 – 0.81 (m, 12H), 0.78 (s, 9H), 0.16 (s, 3H, CH3Si), 0.10 (s, 3H, CH3-Si), 0.08 (s, 3H, CH3-Si), –0.05 (s, 3H, CH3-Si). 13C NMR (100 MHz,
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CDCl3) δ 170.91, 166.79, 136.88, 134.94, 128.73, 116.79, 101.61, 100.56, 99.33, 81.61, 76.65,
75.07, 74.30, 73.54, 73.30, 72.60, 68.75, 66.94, 62.55, 39.65, 33.97, 32.29, 28.95, 25.83(3),
25.80(3), 25.02, 22.85, 21.00, 18.82, 18.10, 17.69, 16.75, 14.28, 14.19, 12.05, –3.06, –3.9, –4.17,
–4.22.

1-Nonen-4S-yl 3-O-tigloyl-2-O-tert-butyldimethylsilyl-β-D-glucopyranosyl-(1→2)-4-Oacetyl-3-O-tert-butyldimethylsilyl-β-D-fucopyranoside 2.40. Compound 2.39c (298.4 mg, 0.35
mmol) was dissolved in a 70% solution of acetic acid and water (10 mL). The reaction mixture
was stirred at 70 oC for 1 hour at which point TLC (silica, 1:3 EtOAc–hexanes) showed it was
complete. The reaction was concentrated and then co-evaporated with toluene (3 x 5 mL). The
residue was purified by column chromatography (silica, EtOAc–hexanes, 1:3 → 1:2) and gave
compound 2.40 (165.0 mg, 58%) as a white foam. [α]D25 +15.4° (c 1 CHCl3). 1H NMR (400
MHz, CDCl3) δ 6.96 – 6.85 (m, 1H, Me-CH=C(Me)-C=O), 5.90 – 5.79 (m, 1H, CH2=CH-CH2-),
5.11 – 5.01 (m, 2H, CH2=CH-CH2-), 5.01 – 4.90 (m, 3H, H-1-Glup, H-3-Glup, H-4-Fucp), 4.31
(d, J = 7.6 Hz, 1H, H-1-Fucp), 4.08 (t, J = 8.4 Hz, 1H, H-2-Fucp), 3.88 (dd, J = 12.0, 3.6 Hz, 1H,
H-6-Glup), 3.85 (dd, J = 9.2, 3.6 Hz, 1H, H-3-Fucp), 3.77 (dd, J = 12.0, 4.4 Hz, 1H, H-6-Glup),
3.69 – 3.56 (m, 3H, H-4-Glup, H-5-Fucp, -CH2-CH-CH2 -), 3.55 – 3.49 (m, 1H, H-2-Glup), 3.40
– 3.31 (m, 1H, H-5-Glup), 2.50 – 2.28 (m, 4H), 2.13 (s, 3H, CH3-C=O), 1.88 – 1.78 (m, 6H,
CH3-CH-C(CH3)-C=O), 1.60 – 1.46 (m, 2H), 1.40 – 1.22 (m, 6H), 1.14 (d, J = 6.4 Hz, 3H, H-6Fucp), 0.97 – 0.83 (m, 12H), 0.80 (s, 9H), 0.15 (s, 3H, CH3-Si), 0.11 (s, 6H, 2 × CH3-Si), 0.05
(d, J = 11.9 Hz, 3H, CH3-Si). 13C NMR (100 MHz, CDCl3) δ 170.91, 169.14, 138.60, 134.79,
128.19, 116.91, 101.62, 99.97, 81.53, 79.16, 75.32, 74.35, 73.89, 73.36, 73.27, 70.76, 68.81,
62.14, 39.55, 33.88, 32.13, 25.83(3), 25.79(3), 25.32, 22.72, 21.01, 18.06, 17.59, 16.70, 14.39,
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14.02, 11.97, –3.00, –3.94, –4.21, –5.17.
Preparation of Ring-Closed Intermediate

Diene 2.41. DCC (50.3 mg, 0.241 mmol) was added in one portion to a 0 ºC CH2Cl2 (10
mL) solution of 2.40 (175.9 mg, 0.219 mmol), 4-oxonon-8-eneoic acid 2.6 (41.0 mg, 0.241
mmol) and 4-dimethylaminopyridine (DMAP) (2.5 mg, 0.022 mmol). The reaction was allowed
to warm to ambient temperature and stirred overnight. At this point, TLC (silica, 1:3 EtOAc–
hexanes) showed the reaction was complete. The reaction mixture was diluted with ether (20 ml)
and hexanes (10 ml), stirred for 20 minutes then filtered thru a pad of celite using ether (20 ml)
as the eluent and the filtrate concentrated in vacuo. The residue was purified by column
chromatography (silica, EtOAc–hexanes, 1:6) gave diene 2.41 (110.0 mg, 55%) as a colorless
syrup. [α]D25 +4.2° (c 1 CHCl3). 1H NMR (300 MHz, CDCl3) δ 7.00 – 6.89 (m, 1H, Me-CHC(Me)-C=O), 5.95 – 5.69 (m, 2H, 2 x CH2=CH-CH2-), 5.12 – 4.89 (m, 7H, 2 × CH2=CH-CH2-,
H-1-Glup, H-3-Glup, H-4-Fucp), 4.41 (dd, J = 12.0, 4.4 Hz, 1H, H-6-Glup), 4.39 (d, J = 8.0 Hz,
1H, H-1-Fucp), 4.35 – 4.33 (dd, J = 12.0, 2.0 Hz, 1H, H-6-Glup), 4.08 (t, J = 9.2, 7.6 Hz, 1H, H2-Fucp), 3.90 (dd, J = 9.2, 3.6 Hz, 1H, H-3-Fucp), 3.70 – 3.49 (m, 4H, H-2-Glup, H-4-Glup, H5-Fucp, -CH2-CH-CH2-), 3.48 – 3.40 (m, 1H, H-5-Glup), 2.94 (d, J = 4.8 Hz, 1H, OH), 2.82 –
2.55 (m, 4H), 2.52 – 2.41 (m, 2H), 2.38 (t, J = 6.0 Hz, 2H), 2.13 (s, 3H, CH3-C=O), 2.11 – 2.01
(m, 2H), 1.89 – 1.77 (m, 6H, CH3-CH-C(CH3)-C=O), 1.76 – 1.65 (m, 4H), 1.42 – 1.21 (m, 6H),
1.14 (d, J = 6.4 Hz, 3H, H-6-Fucp), 0.97 – 0.85 (m, 12H), 0.80 (s, 9H), 0.15 (s, 3H, CH3-Si),
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0.11 (s, 6H, 2 × CH3-Si), 0.04 (s, 3H, CH3-Si). 13C NMR (75 MHz, CDCl3) δ 208.66, 173.08,
170.95, 169.08, 138.67, 137.89, 134.99, 128.20, 116.87, 115.31, 101.11, 99.95, 80.99, 79.01,
74.25, 73.87, 73.80, 73.43, 70.40, 68.84, 63.57, 41.82, 39.59, 37.13, 33.77, 33.03, 32.26, 27.70,
25.83(3), 25.82(3), 25.32, 22.85, 22.71, 21.05, 18.09, 17.63, 16.72, 14.46, 14.26, 12.04, –3.08, –
3.94, –4.24, –5.13.

RCM Product 2.42. To a solution of diene 2.41 (110.0 mg, 0.12 mmol) in CH2Cl2 (40
mL) was added Hoveyda-Grubbs catalyst 2nd generation (7.2 mg, 0.01 mmol) in one portion at
room temperature. The reaction mixture was refluxed for 4 h. At this point, TLC (silica, 1:2
EtOAc–hexanes) showed the reaction was complete. The reaction was cooled to ambient
temperature and then concentrated. Flash chromatography (silica, EtOAc–hexanes, 1:4 → 1:2)
gave isomers 2.42 (92.8 mg, 87%) as a white foam which was not fully characterized. The
obtained isomer was subjected to hydrogenation in next step and the product was fully
characterized.
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Completion of C11 Epimer

Hydrogenation Product 2.43. To a solution of cycloalkene 2.42 (51.4 mg, 0.055 mmol) in
EtOH (2 mL) was added Wilkinson’s catalyst (22 mg, 0.024 mmol) in one portion at room
temperature. The reaction was then stirred under an atmosphere of hydrogen (1 atm) overnight.
At this point, TLC (silica, 1:2 EtOAc–hexanes) showed the reaction was complete. The reaction
mixture was filtered thru a pad of celite using EtOAc (2 mL) as the eluent and the resulting
filtrate concentrated. Flash chromatography (silica, EtOAc–hexanes, 1:5 → 1:3) gave 2.43 (36.1
mg, 70%) as a colorless syrup. [α]D25 +18.0° (c 1 CHCl3). 1H NMR (300 MHz, CDCl3) δ 7.00 –
6.89 (m, 1H, Me-CH-C(Me)-C=O), 5.03 – 4.85 (m, 3H, H-1-Glup, H-3-Glup, H-4-Fucp), 4.51
(m, 1H, H-6-Glup), 4.47 (br, 1H, H-1-Fucp), 4.35 – 4.21 (m, 2H, H-6-Glup, H-2-Fucp), 3.99 –
3.89 (m, 1H, H-3-Fucp), 3.72 – 3.61 (m, 1H, H-5-Fucp), 3.59 (br, 1H, H-5-Glup), 3.51 – 3.40
(m, 3H, H-2-Glup, H-4-Glup, -CH2-CH-CH2 -), 3.08 – 2.95 (m, 1H, OH), 2.95 – 2.89 (m, 1H),
2.78 – 2.60 (m, 3H), 2.60 – 2.48 (m, 1H), 2.38 – 2.27 (m, 1H), 2.12 (s, 3H, CH3-C=O), 1.89 –
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1.78 (m, 6H, CH3-CH-C(CH3)-C=O), 1.75 – 1.51 (m, 6H), 1.49 – 1.21 (m, 12H), 1.12 (d, J = 6.4
Hz, 3H, H-6-Fucp), 0.95 – 0.86 (m, 12H), 0.79 (s, 9H), 0.16 (s, 3H, CH3-Si), 0.12 (s, 3H, CH3Si), 0.11 (s, 3H, CH3-Si), 0.05 (s, 3H, CH3-Si). 13C NMR (75 MHz, CDCl3) δ 210.09, 172.51,
170.93, 169.37, 138.89, 128.11, 99.84, 100.21, 79.44, 74.29, 74.08, 73.79, 73.54, 61.08, 68.65,
63.78, 41.74, 37.21, 33.27, 32.78, 32.27, 28.83, 26.96, 26.72, 25.97, 25.85(6), 24.94, 23.04,
22.71, 22.62, 21.05, 18.11, 17.66, 16.56, 14.47, 14.19, 12.04, –3.25, –3.88, –4.27, –5.24.

Compound 2.44. To a cold (0 oC) solution of compound 2.43 (28.1 mg, 0.030 mmol) and
DMAP (9.0 mg, 0.060 mmol) in pyridine (2 mL) was added cinnamoyl chloride (20.1 mg, 0.120
mmol). The reaction mixture was allowed to warm to ambient temperature and stirred for 24 h.
At the end of this time, TLC (silica, 1:2 EtOAc–hexanes) indicated that the reaction was
complete. The reaction was quenched with MeOH (10 µL) and diluted with CH2Cl2 (10 mL),
washed with 1 M HCl (10 mL), saturated aqueous NaHCO3 (10 mL), and dried (Na2SO4). The
solvent was evaporated under vacuum and the residue was purified by column chromatography
(silica, EtOAc–hexanes, 1:6) to afford compound 2.44 (27.5 mg, 86%) as a white foam. [α]D25 –
1.8° (c 0.5 CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 16.0 Hz, 1H, Ph-CH=C-), 7.54 –
7.47 (m, 2H, 2 × ArH), 7.44 – 7.35 (m, 3H, 3 × ArH), 6.85 – 6.75 (m, 1H, Me-CH-C(Me)-C=O),
6.33 (d, J = 16.0 Hz, 1H, Ph-CH=CH-), 5.25 (t, J = 9.2 Hz, 1H, H-3-Glup), 5.09 – 4.93 (m, 3H,
H-1-Glup, H-4-Glup, H-4-Fucp), 4.51 (br, 1H, H-1-Fucp), 4.34 – 4.27 (m, 1H, H-6-Glup), 4.20
– 4.11 (m, 1H, H-6-Glup), 4.06 – 4.00 (m, 1H, H-3-Fucp), 3.99 – 3.92 (m, 1H, H-2-Fucp), 3.78 –
3.70 (m, 3H, H-5-Glup, H-5-Fucp, -CH2-CH-CH2 -), 3.66 (dd, J = 8.8, 7.6 Hz, 1H, H-2-Glup),
3.01 – 2.70 (m, 2H), 2.78 – 2.46 (m, 4H), 2.12 (s, 3H, CH3-C=O), 1.76 – 1.70 (m, 9H), 1.70 –
1.55 (m, 3H), 1.46 – 1.22 (m, 12H), 1.12 (d, J = 6.4 Hz, 3H, H-6-Fucp), 0.99 – 0.84 (m, 12H),
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0.80 (s, 9H), 0.20 (s, 3H, CH3-Si), 0.13 (s, 3H, CH3-Si), 0.12 (s, 3H, CH3-Si), 0.03 (s, 3H, CH3Si). 13C NMR (100 MHz, CDCl3) δ 210.05, 172.06, 170.94, 166.95, 165.80, 146.27, 138.03,
134.11, 130.57, 128.87(2), 128.29(2), 128.17, 116.70, 100.06, 99.99, 74.97, 73.95, 73.77, 71.63,
70.07, 68.61, 41.69, 37.14, 33.76, 31.94, 28.75, 27.88, 27.40, 25.88(3), 25.82(3), 24.89, 24.72,
22.97, 22.71, 21.05, 18.12, 17.71, 16.61, 14.40, 14.14, 11.94, –3.49, –3.85, –4.34, –5.27.

11R epimer 2.45. To a solution of 2.44 (20.0 mg, 0.019 mmol) in THF (2 mL) was added
TBAF (1M solution in THF, 0.11 mL, 0.113 mmol) at -10 oC. The reaction mixture was stirred at
the same temperature for 4 h at which point TLC (silica, 1:1 EtOAc–hexanes) showed it was
complete. The reaction mixture was diluted with Et2O (10 mL), washed with 1M HCl (10 mL),
saturated NaHCO3 (10 mL), and brine (5 mL). The aqueous layer was extracted with Et2O (20
mL x 2). The combined organic layers were dried over Na2SO4 and concentrated under reduced
pressure. The residue was purified by column chromatography (silica, EtOAc–hexanes, 1:2 →
1:1) gave compound 2.45 (12.0 mg, 77%) as a white foam. [α]D25 –17.0° (c 1.0 CHCl3). 1H NMR
(400 MHz, CDCl3). 1H NMR (400 MHz, CDCl3) δ 7.68 (d, J = 16.0 Hz, 1H, Ph-CH=C-), 7.55 –
7.48 (m, 2H, 2 × ArH), 7.43 – 7.35 (m, 3H, 3 × ArH), 6.93 – 6.84 (m, 1H, Me-CH-C(Me)-C=O),
6.38 (d, J = 16.0 Hz, 1H, Ph-CH=CH-), 5.23 (t, J = 9.6 Hz, 1H, H-4-Glup), 5.20 – 5.16 (m, 2H,
H-3-Glup, H-4-Fucp), 4.67 (d, J = 8.0 Hz, 1H, H-1-Glup), 4.22 (br, 1H, OH), 4.49 (dd, J = 12.4,
3.6 Hz, 1H, H-6-Glup), 4.46 (d, J = 7.6 Hz, 1H, H-1-Fucp), 4.16 (dd, J = 12.4, 2.4 Hz, 1H, H-6Glup), 3.95 – 3.86 (m, 2H, OH, H-3-Fucp), 3.85 – 3.81 (m, 1H, H-5-Glup), 3.81 – 3.66 (m, 4H,
H-2-Glup, H-2-Fucp, H-5-Fucp, -CH2-CH-CH2-), 3.00 – 2.91 (m, 1H), 2.75 – 2.42 (m, 5H) 2.20
(s, 3H, CH3-C=O), 1.80 – 1.75 (m, 6H, CH3-CH-C(CH3)-C=O), 1.75 – 1.70 (m, 2H), 1.70 – 1.52
(m, 4H), 1.51 – 1.20 (m, 12H), 1.19 (t, J = 6.4 Hz, 3H, H-6-Fucp), 0.88 (t, J = 6.8 Hz, 3H). 13C
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NMR (100 MHz, CDCl3) δ 209.40, 171.76, 171.50, 168.22, 165.60, 146.24, 139.11, 134.00,
130.69, 128.95(2), 128.27(2), 127.75, 116.71, 103.13, 97.95, 78.48, 77.45, 75.99, 74.56, 72.66,
72.15, 71.75, 69.22, 68.61, 62.46, 41.95, 37.38, 33.15, 32.57, 32.05, 29.71, 28.79, 28.12, 27.44,
24.68, 23.50, 23.14, 22.63, 20.96, 16.34, 14.54, 14.10, 12.04. HRMS for C44H62NaO15 (M+Na)+
853.3981. Found: 853.3986
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DEVELOPMENT OF A SYNTHESIS TO ACCESS TAIL-MODIFIED
ANALOGS OF IPOMOEASSIN F

Having already demonstrated the importance of the aglycon’s chiral center and knowing the
major role the length of the aglycon plays in the bioactivity of ipomoeassin F, we sought to
further investigate this key component of the ipomoeassins. As previously mentioned, the only
difference between ipomoeassin F and ipomoeassin A are two methylene units in the tail of the
aglycon so we were curious if further increasing the length, and thus increasing the lipophilicity,
of the aglycon could improve potency. If this region of the molecule could tolerate modification,
it would also be interesting to see what other functional groups could be tolerated and what effect
they would have.
In order to investigate this region of the molecule, a new synthetic route would need to be
established. While we could synthesize modified aglycons and attach them with our current
synthesis (as demonstrated with the epimer), this really would be inefficient for the synthesis of a
small library of analogs as each new compound would need to be synthesized from scratch.
Though we explored a few strategies, ultimately we decided the most practical and flexible route
would be one that gave us some type functional handle which could be modified either in the
final step, or at least near the final step of the synthesis.
Retrosynthetic Strategy
As we set out to design a synthesis that would allow the tail of the aglycon to be
modified, we decided incorporating a hydroxyl group into the aglycon would give us the most
flexibility in the way of analog synthesis. With a terminal hydroxyl group in the tail, we would
be able to attach a wide variety of compounds through mild esterification conditions without
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disturbing the other esters already decorating the periphery of the molecule. We acknowledged
that this strategy would be incorporating other variables besides solely modifying the length of
the tail, but we were hopeful that an ester functionality could be tolerated at this position and any
decrease in lipophilicity due to the ester could be overcome with a sufficiently lipophilic
sidechain. We were also encouraged by results previously obtained by our lab during the
synthesis of bioisosteric 5-oxa/aza analogs of ipomoeassin F80. In this work, the ketone
functionality of the aglycon was substituted for various amides and esters. Several of these
analogs (Figure 3-1) maintained quite similar potency to ipomoeassin F, encouraging us that
perhaps an ester could be tolerated in the tail of the aglycon as well. Another earlier successful
modification to the aglycon from our lab removed the ketone from the aglycon altogether with
very little drop in activity81.

Figure 3-1. Previously Synthesized Aglycon Modified Analogs
When designing the synthesis, we initially planned to use a route as close as possible to
our original ipomoeassin F/epimer route so that most of the chemistry would already be
established. The main challenge would be the addition of an extra hydroxyl group in the aglycon
that would need to be protected throughout the entirety of the synthesis. Ideally this group would
be orthogonal to the other protecting group so that it could be selectively removed at the end of
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the synthesis and the corresponding hydroxyl group could be modified. We hypothesized that the
primary alcohol on the tail would be more selective towards esterification reactions than the
secondary carbohydrate alcohols, but orthogonal protection would free us from needing to rely
on any selectivity differences. Not only did we desire orthogonal protection, but we also needed
a group that could withstand the various reaction conditions throughout the entirety of the
synthesis which limited our selection of possible protecting groups considerably. In the end, we
had to stray from our initial route in a few locations which will be described in detail below.

Scheme 3-1. Initial Retrosynthetic Strategy
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Synthesis of the Protected Aglycon
Fundamental to the success of our synthesis was the selection of a suitable protecting
group for the hydroxyl group in the tail of the aglycon. We began the synthesis with S-glycidol
as our source of chirality as well as for the inclusion of a hydroxyl group that we would be able
to modify. We started by protecting the alcohol and then opening up the epoxide with
vinylmagnesium bromide to form the protected aglycon. We initially chose the p-methoxybenzyl
(PMB) protecting group as it should be stable enough to remain in place throughout the synthesis
but be easily removed under mild oxidizing condition without disturbing the TBS protecting
groups we anticipated using to protect the secondary hydroxyl groups of the glycon. However,
after further optimization we found the tert-butyldiphenylsilyl (TBDPS) protecting group to be
more suitable.
Preparation of the PMB Protected Aglycon

Originally, we chose to protect the aglycon using PMB due to its stability and desirable
deprotection conditions. We commenced by reacting commercially available S-glycidol with
PMBCl using NaH as the base to furnish the protected glycidol. We could then open the epoxide
with vinylmagnesium bromide to form the chiral alcohol 3.5 which would be used as the aglycon
in a subsequent glycosylation with the fucosyl donor.

Scheme 3-2. Synthesis of the PMB Protected Aglycon
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We carried on with the synthesis by coupling this PMB protected aglycon with the
fucosyl donor 3.6 via glycosylation catalyzed by the Lewis acid TMSOTf under anhydrous
conditions. A subsequent deacetylation smoothly gave fucoside 3.8 in good yield. At this stage in
the synthesis we rely on a regioselective introduction of TBS to the 3-O-fucp position.
Unfortunately, we were unable to replicate our previous results with this reaction on this
particular substrate. It seems the selectivity among the three hydroxyl groups is heavily
dependent on the aglycon of the substrate. While using the OPMB containing aglycon, only 20%
yield of the desired compound was isolated. While the 3-O position is still the most reactive
position, the yield seems to be hindered by potential hydrogen bonding with the OPMB group of
the aglycon. Although we could use a different route to synthesize the desired fucoside acceptor,
we would have to drastically lengthen the synthetic route so we decided it would be more
efficient to first investigate other aglycon protecting groups before altogether changing our
strategy.

Scheme 3-3. Synthesis of OPMP Fucoside Acceptor
Preparation of the TBDPS-Protected Aglycon
Hypothesizing that the 3-O-fucp position was unreactive due to hydrogen bonding from
the PMB, we decided to try TBDPS. While this wasn’t our most desirable choice due to lack of
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selectivity with its removal, we were drawn to its robustness and were fairly confident in its
stability towards the various reaction conditions it would encounter. The synthesis began in a
similar fashion, reacting S-glycidol with TBDPSCl and imidazole to protect the free hydroxyl
group. Upon successful protection, we once again opened the epoxide using vinylmagnesium
bromide to afford the desired TBDPS-protected chiral alcohol 3.11.

Scheme 3-4. Synthesis of the TBDPS Protected Aglycon
With the new aglycon in hand we once again attempted to synthesize the fucoside
acceptor. Using the same sequence of reactions, we coupled the aglycon and the fucosyl donor
which upon deacetylation with NaOMe in MeOH gave fucoside 3.13. To our delight, the
following TBS introduction gave the desired selectivity and with good conversion, so we decided
to carry forward using TBDPS as our protecting group of choice for the aglycon.

Scheme 3-5. Synthesis of OTBDPS Fucoside Acceptor
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Synthesis of the Glucosyl Donor
With the successful completion of the protected fucoside acceptor, we then turned our
attention to the glucosyl donor. One of the biggest hurdles for quickly scaling up more
intermediates for our original ipomoeassin F (and epimer) synthesis was the synthesis of the
glucosyl donor. Our need for the α-PMP glucoside required us to wait for days for the reaction to
finish and also required a difficult large-scale purification to remove any anomer that might
remain. The protecting strategy used also required more steps. Fortunately, during an effort in
our lab to study the role of the tiglate and cinnamate moietys58, a new route for the glucosyl
donor was established which we also opted to use for this work.
The synthesis begins with D-glucose which was globally acetylated. Glycosylation with
thiotoluene followed by deacylation gave the thioglycoside 3.16. Subsequent isopropylidenation
efficiently protected the 4- and 6-O positions leaving the other positions open for orthogonal
protection with levulinic acid. The anomeric thiotoluene could then be removed upon treatment
with NBS and the corresponding hemiacetal was converted to the trichloroacetimidate glucosyl
donor 3.20.

Scheme 3-6. Synthesis of the Glucosyl Donor
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Synthesis of Macrocyclic Disaccharide Intermediate
After obtaining both the glucosyl donor and the fucoside acceptor, a regio- and
stereoselective glycosylation provided the disaccharide intermediate in good yield. An acylation
of the remaining free hydroxyl group afforded compound 3.21. At this point,
deisopropylidenation followed by a regioselective esterification successfully introduced the other
fragment of the aglycon to furnish the RCM precursor 3.23. RCM catalyzed by Hoveyda-Grubbs
second generation catalyst followed by hydrogenation completed the formation of the
macrocycle. In this case, the hydrogenation could be performed using palladium on carbon as the
catalyst since no other unsaturated groups would be present until after the reduction. Following
hydrogenation, the cinnamate moiety was introduced to the 4-O-glcp position via Mukaiyama
esterification to give intermediate 3.25.

Scheme 3-7. Synthesis of Ring-Closed Intermediate
Synthesis of Key Intermediate for Analog Synthesis
Following the installation of the cinnamate, we could begin to attempt our end strategy.
We first removed the levulinoyl protecting groups using hydrazine acetate and then
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regioselectively introduced the tiglate to the 3-O-glcp position. From here our strategy was to do
a global deprotection, removing the TBDPS, TBS, and ketal in one pot, and attempt to
selectively modify the primary tail hydroxyl group. Because we used TBDPS as our protecting
group for the tail, we were unable to selectively deprotect this position, but we hoped that a
regioselective esterification would be possible since we anticipated the terminal tail hydroxyl
group to be less hindered than the secondary glycon hydroxyl groups and thus more reactive.
Unfortunately, all of the esterification conditions we tried resulted in an inseparable mixture of
regioisomers. Triol 3.29 was tested in our cytotoxicity assay as a new analog to understand what
kind of an impact such an increase in hydrophilicity would have on activity. As expected, this
compound showed a decrease of more than 400-fold when compared to ipomoeassin in MDAMB-231 or MCF7 cells (Table 3-1).

Scheme 3-8. Synthesis of Triol Intermediate
Knowing that a regioselective modification of the terminal hydroxyl group might not be
possible, we decided to employ an alternative strategy. We hoped that an introduction of a bulky
protecting group would be selective to the primary position. Our first trial was with a trityl group
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which is normally very selective to primary alcohols. However, it seemed our terminal hydroxyl
group was still too hindered. Even with a large excess of trityl chloride, no reaction at all was
observed. Since we knew TBDPS had previously been installed at that position, we attempted to
reinstall it. Fortunately, we were able to introduce it with good selectivity upon addition of an
excess of TBDPSCl. At this stage of the synthesis we needed to now install an orthogonal
protecting group at the remaining secondary hydroxyl positions so that we could selectively
remove the TBDPS group. For this we chose a chloroacetyl group since it was small enough to
be easily introduced and would be stable to the acidic conditions needed to remove the TBDPS.
This strategy worked in our favor and the chloroacetyl groups were easily installed using
Steglich esterification conditions and the TBDPS group was subsequently removed using CSA.

Scheme 3-9. Completion of Intermediate for Further Analog Synthesis
Synthesis of Tail-Modified Ipomoeassin Analogs
Having successfully developed a route to enable the synthesis of multiple analogs with a
modified aglycon, we chose a small set of ester analogs to test the effect of lipophilicity and the
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tolerability of different functional groups. For an initial study, we attempted to introduce a series
of aliphatic chains of increasing length as well as an aromatic group. The ester was first formed
via Mukaiyama esterification. The solvent was then evaporated and DABCO and ethanol were
added to remove the chloroacetyl protecting groups in the same pot. The final compounds could
then be purified by chromatography and submitted to a cytotoxicity assay. Unfortunately, two of
the isolated compounds, the acetyl and hexyl ester analogs, were determined to have an incorrect
structure. The two successful analogs, the benzyl and butyl esters, provided some useful
cytotoxicity data summarized in Table 3-1. As we expected, the butyl ester analog showed an
increase in potency relative to the corresponding alcohol, although still not as potent as
ipomoeassin F. While the overall length of the aglycon tail is similar to that of ipomoeassin F,
the overall lipophilicity was decreased by the presence of the ester and presumably is responsible
for the decrease in activity. In the future we would like to investigate if lengthening the ester
could make up for this difference in potency. The benzyl ester analog also showed improved
potency but much less than the butyl analog indicating that this area of the molecule is probably
not tolerant of aromatic groups. This exploratory synthesis unfortunately did not provide enough
material for a large array study, but with the establishment of a viable route for the synthesis of
tail-modified ipomoeassin analogs, a future scale-up of material could give access to a new
library of ipomoeassin analogs for further SAR studies.

Scheme 3-10. Synthesis of Tail-Modified Analogs
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MDA-MB-231 (IC50, nM)
MCF-7 (IC50, NM)

Ipom F
Cmpd 3.29
Cmpd 3.33
6.3
2722.2
700.3
36.5
19013.2
1960.2
Table 3-1. Cell Cytotoxicity Data

Cmpd 3.34
858.7
4254.7

Experimental Procedures
Reactions were carried out in oven-dried glassware. All reagents were purchased from
commercial sources and were used without further purification unless specified. Except stated
otherwise, all reactions were carried out under a nitrogen atmosphere and monitored by thin
layer chromatography (TLC) using Silica Gel GF254 plates (Agela) with detection by charring
with 5% (v/v) H2SO4 in EtOH or by visualizing in UV light (254 nm). Column chromatography
was performed on silica gel (230–450 mesh, Sorbent). The ratio between silica gel and crude
product ranged from 100 to 50:1 (w/w). NMR data were collected on a Bruker 300 or 400 MHz
NMR spectrometer and a Bruker 300 or 400 MHz system. 1H NMR spectra were obtained in
deuterochloroform (CDCl3) with chloroform (CHCl3, δH = 7.27 for 1H) as an internal reference.
13C NMR spectra were proton decoupled and were in CDCl3 with CHCl3 (δC = 77.0 for 13C)
as an internal reference. Chemical shifts are reported in ppm (δ). Data are presented in the form:
chemical shift (multiplicity, coupling constants, and integration). 1H data are reported as though
they were first order. The errors between the coupling constants for two coupled protons were
less than 0.5 Hz, and the average number was reported. Proton assignments, when made, were
done so with the aid of COSY NMR spectra. For some compounds, HSQC and HMBC NMR
were also applied to assign the proton signals. Optical rotations were measured on an Autopol
III Automatic Polarimeter at 25 ± 1 oC for solutions in a 1.0 dm cell. High resolution mass
spectrum (HRMS) and were acquired in the ESI mode.
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Synthesis of the Tail-Protected Aglycon

(R)-tert-butyl(oxiran-2-ylmethoxy)diphenylsilane 3.10. A stirred solution of (S)-glycidol
(1.0 g, 1.0 eq) and imidazole (2.02 g, 2.2 eq) in DCM (15 mL) was cooled to 0 oC and TBDPSCl
(4.56 mL, 1.2 eq) was slowly added under a nitrogen atmosphere. The reaction was allowed to
warm to RT and was stirred overnight at which point TLC (EtOAc-Hexanes, 1:7) showed the
reaction to be complete. The reaction mixture was diluted with water and extracted with DCM
(x3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered,
and concentrated to dryness. The crude reside was purified via column chromatography (silica,
EtOAc-Hexanes, 1:20 → 1:10) to give compound 3.10 (3.92 g, 93%).

(R)-1-((tert-butyldiphenylsilyl)oxy)pent-4-en-2-ol 3.11. A solution of compound 3.10
(0.182 g, 1.0 eq) and CuCN (0.010 g, 0.2 eq) in THF (5 mL) was cooled to -30 oC and stirred for
10 min. Vinylmagnesium bromide (1.24 mL, 1.5 eq, 0.7 M in THF) was then slowly dripped in
and stirred for 30 min before slowly warming to 0 oC and stirring for an additional 30 minutes at
which point TLC (EtOAc-Hexanes, 1:7) showed the reaction to be complete. The reaction was
then quenched with saturated NH4Cl (aq.) still at 0 oC. The mixture was extracted with diethyl
ether (3 x 10 mL) and the combined organic layers were washed with brine, dried over sodium
sulfate, filtered evaporated and concentrated. The residue was purified via column
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chromatography (silica, EtOAc-Hexanes, 1:20 → 1:10) to give alcohol 3.11 (0.169 g, 85%).

Synthesis of TBDPS-Protected Fucoside Acceptor

Peracetylated fucoside 3.12. A solution of fucosyl donor 3.6 (5.02 g, 1.1 eq) and acceptor
3.11 (3.62 g, 1.0 eq) in dry DCM (100 mL) was stirred over 4Å molecular sieves (5 g) for 30 min
and then chilled to -78 oC. TMSOTf (0.209 mL, 0.1 eq) was added to the chilled solution and the
reaction was slowly warmed to RT over 3 hours and left to stir overnight at which point TLC
(EtOAc-hexanes, 1:2) showed the reaction to be mostly complete. The reaction was quenched
with Et3N (0.3 mL), filtered and purified by chromatography (silica, EtOAc-Hexanes, 1:10 →
1:6). After purification, NMR and TLC showed some impurities to remain but the crude residue
was taken to the next step without any complications. Following the deprotection the triol could
be easily separated from the impurities and fully characterized.

Fucoside 3.13. A solution of crude compound 3.12 (4.98 g) was dissolved in MeOH at
RT and NaOMe was stirred in until the solution was sufficiently basic (pH ~10). The reaction
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was left to stir overnight at which point TLC (EtOAc-Hexanes, 1:2) showed all of the SM had
been consumed. The reaction was then neutralized by the addition of ion-exchange resin (to pH
~7). The suspension was filtered and then concentrated to dryness. The residue was purified via
column chromatography (silica, EtOAc-Hexanes, 1:3 → 1:0) to give compound 3.13 (4.14 g,
80% over 2 steps).

Fucoside acceptor 3.14. To a stirred solution of triol 3.13 (1.46 g, 1 eq) and imidazole
(0.61 g, 3 eq) in DCM (40 mL) was added TBSCl (0.63 g, 1.4 eq) at 0 oC. The reaction was
allowed to warm to RT after addition of TBSCl and was left to stir overnight at which point TLC
(EtOAc-hexanes, 1:2) showed all the SM had been consumed and one major product was
observed as well as small amounts of a regioisomer. The reaction mixture was transferred to a
separatory funnel and washed with water (2 x 25 mL). The aqueous layers were extracted with
DCM (2 x 25 mL) and the combined organic layers were washed with brine (30 mL), dried over
sodium sulfate, filtered, and concentrated to dryness. The residue was purified via column
chromatography (silica, EtOAc-Hexanes, 1:10 → 1:8) to give the desired compound 3.14 (1.35
g, 75%). 1H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 6.8 Hz, 4H), 7.46 – 7.38 (m, 6H), 5.92 –
5.82 (m, 1H), 5.12 (t, J = 14.1 Hz, 2H), 4.17 (d, J = 7.8 Hz, 1H), 3.98 – 3.95 (m, 1H), 3.79 – 3.73
(m, 1H), 3.64 – 3.59 (m, 2H), 3.53 – 3.44 (m, 3H), 2.66 – 2.59 (m, 2H), 2.37 – 2.30 (m, 2H),
1.24 (d, J = 6.5 Hz, 3H), 1.09 (s, 9H), 0.93 (s, 10H), 0.15 (d, J = 8.1 Hz, 6H). 13C NMR (100
MHz, CDCl3) δ 135.59, 135.54, 135.06, 133.66, 133.41, 129.60, 129.59, 127.60, 127.59, 117.49,
103.17, 79.63, 77.32, 77.00, 76.68, 74.68, 72.05, 71.75, 70.04, 65.78, 36.43, 26.86, 25.73, 19.22,
18.07, 16.22, -4.44, -5.03.
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Synthesis of the Glucosyl Donor

1,2,3,4,6-pentaacetate-α,β-D-glucopyranose 3.15b. D-Glcp 3.15 (20.65 g, 0.14 mol) was
slowly added to a mixture of acetic anhydride (90 mL) and HClO4 (0.7 mL) over 0.5-1 hr at 0 oC.
The reaction was allowed to warm slowly over 30 mins as the reaction turned from yellow to
clear. TLC (silica, 2:1 Hex-EtOAc) showed the reaction to be complete. The reaction mixture
was co-evaporated with toluene (150 mL) three times after quenching reaction with Et 3N. The
residue was dissolved in sat. aq. NaHCO3 (100 mL) and extracted twice with DCM (150 mL).
The organic layers were combined, dried with Na2SO4, filtered, and concentrated under reduced
pressure. Compound 3.15b was carried on to the next step without further purification. 1H NMR
(300 MHz; CDCl3) δH 6.29 (d, J = 3.2 Hz, 1 H, H-1α), 5.67 (d, J = 7.7 Hz, c0.4 H, H-1β), 5.445.35 (dd, J = 10.2 and 10.0 Hz, 1 H, H-3α), 5.29-5.21 (m, 0.4 H, H-3β), 5.17-5.04 (m, 2.8 H, H2α, H-2β, H-4β, H-4α), 4.30-4.26 (m, 1.4 H, H-6α, H-6αβ), 4.12-4.01 (m, 2.4 H, H-6α, H-6β, H-5α),
3.84-3.79 (0.4 H, H-5β), 2.19 (s, 4.2 H), 2.13 (s, 1.2 H), 2.09 (s, 4.2 H), 2.02 (s, 8.4 H). 13C NMR
(75 MHz, CDCl3) δc 170.4, 170.1, 169.5, 169.3, 168.6, 92.0 (C-1β), 89.4 (C-1α), 73.2 (Cβ), 70.6
(Cβ), 70.2 (2Cα,β), 69.5 (Cα), 68.2 (Cα), 61.7 (Cα,β), 21.0, 21.0, 20.8, 20.7.82
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4-(methylthio)phenyl-2,3,4,6-tetraacetate-β-D-glucopyranoside 3.16. Peracetylated
glucose 3.15b (27 g, 69.3 mmol) was dissolved in dry DCM (300 mL) with 4-methylthiophenol
(12.9 g, 138.7 mmol) and cooled to -10 oC. Then, BF3 ∙ OEt2 was slowly added and reaction
stirred 12-48 hrs at RT. The reaction was monitored by TLC (silica, Hex-EtOAc 2:1, Rf = 0.54).
The reaction mixture was slowly poured into crushed ice and stirred for 10 mins. The reaction
was neutralized with careful addition of sat. aq. NaHCO3 (200 mL) and extracted (300 mL x 2)
with DCM. The combined organic layers were dried over NaSO4, filtered, and the solvent
removed under reduced pressure. The residue was purified with column chromatography (silica,
Hex-EtOAc, 5:1-1:1) to give the β-thioGlcp 3.16 in 70% (85% BORSM). 1H NMR (400 MHz,
CDCl3) δH 7.38 (d, J = 7.8 Hz, 2H, 2 ∙ Ar‒H), 7.12 (d, J = 7.8 Hz, 2H, 2 ∙ Ar‒H), 5.20 (t, J = 9.6
Hz, 1H, H-3-Glcp), 5.01 (t, J = 9.6 Hz, 1H, H-4-Glcp), 4.93 (t, J = 9.7 Hz, 1H, H-2-Glcp), 4.62
(d, J = 10.1 Hz, 1H, H-1-Glcp), 4.23-4.14 (m, 2H, H-6-Glcp), 3.69 (ddd, J = 2.3, 4.3, 7.4 Hz, 1H,
H-5-Glcp), 2.34 (s, 3H, S‒Tol‒CH3), 2.08 (s, 3H, ‒CH3), 2.08 (s, 3H, ‒CH3), 2.00 (s, 3H, ‒CH3),
1.99 (s, 3H, ‒CH3).

13

C NMR (100 MHz, CDCl3) δC 170.6 (C=O), 170.1 (C=O), 169.4 (C=O),

169.3 (C=O), 138.7 (C=C), 133.7 ∙ 2 (C=C), 129.6 ∙ 2 (C=C), 127.4 (C=C), 85.7 (C-1), 75.8,
73.8, 69.8, 68.2, 62.1, 21.2 (‒CH3), 20.7 (‒CH3), 20.7 (‒CH3), 20.5(‒CH3), 20.4 (‒CH3).83,84

4-(methylthio)phenyl-β-D-glucopyranoside 3.17. The β-thioGlcp 3.16 (23.6 g, 51.9
mmol) was dissolved in MeOH (200 mL) and catalytic NaOMe (0.280 g, 5.2 mmol). The
reaction was stirred at RT for 6-12 hrs, when the TLC (silica, EtOAc: MeOH 10:1, Rf = 0.15)
showed the reaction to be complete. The reaction was neutralized with Amberlite IR-120 (H) ion
exchange resin and filtered. The solvent was removed under reduced pressure. The crude tetraol
3.17 was used directly in the next step without further purification. 1H NMR (400 MHz,
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CD3OD) δH 7.44 (d, J = 7.7, 2H, 2 ∙ Ar‒H), 7.11 (d, J = 7.8, 2H, 2 ∙ Ar‒H), 4.50 (d, J = 9.5, 1H,
H-1-Glcp), 3.89 (d, J = 2.5, 1H), 3.76-3.71 (m, 2H), 3.59 (t, J = 9.2, 1H), 3.56-3.48 (m, 2H, H5-Glcp), 2.30 (s, 3H, Ph ‒CH3).

13

C NMR (100 MHz, CD3OD) δ 138.5 (C=C), 133.0 ∙ 2 (C=C),

132.2 ∙ 2 (C=C), 130.7 (C=C), 90.8 (C-1), 80.7, 76.5, 71.1, 70.5, 62.7, 21.2 (Ph‒CH3).85

4-(methylthio)phenyl-4,6-O-isopropylidine-β-D-glucopyranoside 3.18. The crude tetraol
3.17 (16.8 g, 58.6 mmol) was dissolved in the minimal amount of DMF (80 mL), then DMP (66
mL, 234 mmol) and catalytic p-TsOH (223 mg, 1.1 mg) were added to the solution at RT. The
reaction was allowed to stir at RT overnight, while monitoring the reaction though TLC (HexEtOAc, 2:1, Rf = 0.49). The reaction was quenched with NEt3 (0.5 mL), diluted with toluene,
and solvent removed under reduced pressure. The crude syrup was dissolved in EtOAc (150
mL), washed with brine, dried over NaSO4, filtered, and the EtOAc under reduced pressure. The
syrup was purified using column chromatography (silica, Hex-EtOAc 4:1→1:2) to the C-4,C-6protected glucoside 3.18 in 75% (15.75 g) clear syrup; 1H NMR (400 MHz, CDCl3) δH 7.40 (d, J
= 8.2 Hz, 2H, 2 ∙ Ar‒H), 7.13 (d, J = 8.1 Hz, 2H, 2 ∙ Ar‒H), 4.58 (d, J = 9.6 Hz, 1H, C-1-Glcp),
3.94 (dd, J = 10.4, 5.2 Hz, 1H), 3.76 (t, J = 10.8 Hz, 1H), 3.68 (t, J = 8.4 Hz, 1H), 3.51 (t, J = 9.6
Hz, 1H), 3.41– 3.27 (m, 2H), 3.10 (br, 1H, ‒OH), 2.90 (br, 1H, ‒OH), 2.61 (s, 3H, Ph‒CH3),
1.49 (s, 3H, O‒C‒CH3), 1.42 (s, 3H, O‒C‒CH3).

13

C NMR (100 MHz, CDCl3) δH 138.68

(C=C), 133.43 ∙ 2 (C=C), 129.84 ∙ 2 (C=C), 127.50 (C=C), 99.80 (O‒C‒O), 88.80 (C-1), 74.91,
72.89, 72.66, 71.52, 61.97, 28.94 (Ph‒CH3), 21.12 (O‒C‒CH3), 19.10 (O‒C‒CH3).
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4-(methylthio)phenyl-2,3-O-levulinoyl-4,6-isopropylidine-β-D-glucopyranoside 3.19.
DCC (23.13 g, 112 mmol) was added in one portion to a cooled solution (0 oC) of DCM (300
mL), the diol 3.18 (12.2 g, 37.3 mmol), levulinic acid (13.0 g, 112mmol), and DMAP (991 mg,
7.4 mmol). The reaction was stirred at RT overnight, as the reaction started to form white
precipitate (DCU), and the reaction turned a reddish-brown color. After TLC (silica, HexEtOAc, 3:1, Rf = 0.58) showed the reaction to be complete the DCM was partially removed
under reduced pressure. The reaction was diluted with Et2O (200 mL) and Hex (100 mL) to
cause the DCU to crash out of the solution. The slurry was filtered through a pad of Celite and
concentrated under reduced pressure. The residue was purified through column chromatography
(silica, Hex-EtOAc, 2:1→1:1) to give the 2,3-lev-glucoside 3.19 in 90% (17.5 g). The material
was carried through to the next step without characterization.

Hemiacetal-2,3-O-levulinoyl-4,6-O-isopropylidene-α,β-D-glucopyranoside 3.19b.

The

2,3-O-lev glucoside 3.19 was dissolved in the mixture of MeCN/H2O (9:1, 108 mL:12 mL) and
cooled to -10 oC. Then, NBS (15.1 mmol, 89.2 mmol) was slowly added over five mins to the
mixture and stirred at -10 oC for 5-10 mins. After TLC (silica, Hex-EtOAc, Rf = 0.51, 0.42) showed
the reaction to be complete, sat. aq. Na2S2O3 (40 mL, orange to clear) was added followed by sat.
aq. NaHCO3 (120 mL). The mixture was partially concentrated under reduced pressure and the
organic layer extracted with DCM (2 x 150 mL). The combined organic layers were collected,
dried over NaSO4, filtered, and concentrated under reduced pressure. The residue was purified
with column chromatography (silica, Hex-EtOAc, 4:1→EtOAc) to the give the α,β-hemiacetal
3.19b in 80%.
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Trichloroacetimidate-2,3-O-levulinoyl-4,6-O-isopropylidene-α,β-D-glucopyranoside
3.20. CCl3CN (8.35 g, 83.0 mmol) and DBU (0.31 mL, 2.01 mmol) were are added to the mixture
of the α,β-hemiacetal 3.19b (8.64 g, 20.8 mmol). The reaction was allowed to stir at RT for 3-5
hrs. as the mixture turned an orange-brown color. The reaction was quenched with 0.5 mL of NEt3
after the TLC (silica Hex-EtOAc 1:1 Rf = 0.65) showed the reaction to be complete. The mixture
was concentrated under reduced pressure. The Schmidt donor 3.20 was obtained in 85% (9.90 g),
after purification by column chromatography (silica, Hex-EtOAc 4:1 →1:1, few drops of NEt3).
[α]25D + 52.4° (c 1 CHCl3). 1H NMR (400 MHz, CDCl3) δH 8.71, 8.64 (2s, 1H, OCNHCCl3), 6.45
(d, J = 4.5 Hz, 1H, H-1-Glcp), 5.49 (t, J = 9.6 Hz, 1H, H-3-Glcp), 5.12 (dd, J = 10.0, 4.0 Hz, 1H,
H-2-Glcp), 3.98 – 3.87 (m, 2H, H-5, H-6-Glcp), 3.84 – 3.68 (m, 2H, H-4-Glcp, H-6-Glcp), 2.90 –
2.46 (m, 8H, 2 ∙ CH3‒C=O(CH2)2C‒O), 2.17 (s, 3H, CH3-C=O(CH2)3C-O), 2.16, 2.15 (2s, 3H,
CH3‒C=O(CH2)2C‒O), 1.49, 1.48 (2s, 3H, (CH3)2C‒O), 1.40, 1.39 (2s, 3H, (CH3)2C‒O).

13

C

NMR (100 MHz, CDCl3) δC 206.3, 206.2, 171.81, 171.7, 160.9, 99.9, 93.6, 90.7, 71.3, 70.3, 69.1,
66.0, 61.94, 37.7, 37.5, 29.7, 29.7, 28.7, 27.8, 27.5, 18.9.

Synthesis of Key Triol Intermediate
Preparation of Ring-Closed Intermediate
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Disaccharide 3.21. To a stirred solution of donor 3.20 (4.01 g, 1.0 eq) and acceptor 3.14
(4.30 g, 1.0 eq) in DCM was added 4 Å molecular sieves at RT. The mixture was stirred for 30
min and cooled to -78 oC. TMSOTf (0.13 mL, 0.1 eq) was then added to the reaction mixture and
left to stir for an hour. After an hour, the reaction was allowed to warm to 0 oC at which point
TLC (EtOAc-hexanes, 1:2) showed the reaction to be complete. The reaction was quenched with
pyridine, filtered, and concentrated to dryness. The crude product was carried on to the next step
without purification. To a cold (0 oC) solution of the crude disaccharide and DMAP (trace) in
pyridine (40 mL) was added acetic anhydride (12 mL). The reaction mixture was heated to 40 oC
and stirred for an additional 24 h, at the end of which time TLC (silica, 1:2 EtOAc–hexanes)
indicated that the reaction was complete. The mixture was concentrated under reduced pressure
and then co-evaporated with toluene (2 × 50 mL) gave the crude product. The residue was
purified by column chromatography (silica, EtOAc–hexanes, 1:3 → 1:2) to afford compound
3.21 (4.84 g, 65% over 2 steps) as a colorless syrup. 1H NMR (400 MHz, CDCl3) δH 7.70 – 7.67
(m, 4H), 7.44 – 7.36 (m, 6H), 6.07 – 5.97 (m, 1H), 5.15 – 5.04 (m, 4H), 4.96 – 4.90 (m, 2H),
4.27 (d, J = 7.6 Hz, 1H), 3.95 – 3.81 (m, 3H), 3.77 – 3.62 (m, 5H), 3.47 (q, J = 6.3 Hz, 1H), 3.29
– 3.22 (m, 1H), 2.84 – 2.51 (m, 10H), 2.43 – 2.37 (m, 1H), 2.17 (d, J = 5.8 Hz, 6H), 2.10 (s, 3H),
1.44 (s, 3H), 1.37 (s, 3H), 1.07 (s, 10H), 0.97 (d, J = 6.4 Hz, 3H), 0.87 (s, 10H), 0.15 (s, 3H),
0.10 (s, 3H). 13C NMR (100 MHz, CDCl3) δC 206.33, 206.11, 171.89, 171.33, 170.65, 135.61,
135.58, 135.08, 133.74, 133.54, 129.53, 127.56, 127.54, 116.69, 102.19, 99.67, 99.37, 81.15,
77.32, 76.68, 75.22, 73.42, 73.37, 73.33, 72.44, 71.53, 68.83, 67.37, 65.60, 62.14, 37.73, 36.19,
29.77, 29.75, 28.88, 27.88, 27.86, 26.83, 25.82, 20.84, 19.21, 18.85, 17.74, 16.34, -4.46, -4.47
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Diol 3.22. CSA (214 mg, 0.20 eq) was added in one portion to a solution of compound
3.21 (4.80 g, 1.0 eq) in MeOH (50 mL) at room temperature. The reaction mixture was stirred for
2 hours at which point TLC (silica, 1:2 EtOAc–hexanes) showed it was complete. The solvent
was removed, and the residue was purified by column chromatography (silica, EtOAc–hexanes,
1:2) gave compound 3.22 (3.37 g, 73%) as a colorless syrup. 1H NMR (400 MHz, CDCl3) δH
7.68 – 7.66 (m, 4H), 7.43 – 7.35 (m, 6H), 6.03 – 5.94 (m, 1H), 5.14 – 4.90 (m, 6H), 4.26 (d, J =
7.7 Hz, 1H), 3.92 – 3.83 (m, 3H), 3.79 – 3.67 (m, 4H), 3.64 – 3.60 (m, 1H), 3.46 (q, J = 6.3 Hz,
1H) 3.41 – 3.39 (m, 2H), 2.85 – 2.77 (m, 3H), 2.71 – 2.51 (m, 6H), 2.39 – 2.31 (m, 2H), 2.17 (d,
J = 8.5 Hz, 6H), 2.11 (s, 3H), 1.06 (s, 9H), 0.97 (d, J = 6.4 Hz, 3H), 0.88 (s, 9H), 0.14 (s, 3H),
0.10 (s, 3H). 13C NMR (100 MHz, CDCl3) δC 208.11, 206.07, 173.06, 171.34, 170.70, 135.58,
135.56, 134.92, 133.74, 133.51, 129.55, 129.53, 127.57, 127.53, 116.89, 102.27, 98.75, 81.62,
77.32, 76.68, 76.24, 74.98, 74.75, 73.47, 73.21, 72.06, 69.72, 68.84, 65.67, 62.00, 38.34, 37.64,
36.22, 29.74, 29.72, 28.08, 27.88, 26.82, 25.75, 20.89, 19.20, 17.66, 16.34, -4.35, -4.60

Diene 3.23. To a stirred solution diol 3.22 (3.32 g, 1.0 eq) in dry DCM (50 mL) was
added 1-methyl-2-chloropyrdium iodide (CMPI) (1.69 g, 2.0 eq), DMAP (203 mg, 0.5 eq), and
the acid 3.26 (0.781 g, 1.1 eq). After the reaction was cooled to 0 oC, NEt3 (3.36 g, 4.62 mL, 10
eq) was added and the reaction was allowed to slowly warm to RT over 1-2 hrs. At this point
TLC showed the reaction to be complete (silica, Hex‒EtOAc 1:1). The reaction was
concentrated under reduced pressure and purified by column chromatography (silica,
Hex−EtOAc, 5:1 → 1:1) to give the diene 3.23 (2.54 g, 64%). 1H NMR (400 MHz, CDCl3) δH
7.69 – 7.66 (m, 4H), 7.43 – 7.35 (m, 6H), 6.09 – 5.99 (m, 1H), 5.83 – 5.73 (m, 1H), 5.14 – 4.89
(m, 8H), 4.44 (dd, J = 12.2, 3.8 Hz, 1H), 4.30 – 4.23 (m, 2H), 3.95 – 3.60 (m, 10H), 3.48 – 3.45
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(m, 3H), 2.82 – 2.76 (m, 3H), 2.73 – 2.48 (m, 6H), 2.44 – 2.35 (m, 3H), 2.16 (d, J = 10.0 Hz,
6H), 2.10 (s, 3H), 2.05 – 1.99 (m, 4H), 1.61 – 1.57 (m 2H), 1.49 – 1.43 (m, 2H), 1.06 (s, 9H),
0.97 (d, J = 6.4 Hz, 3H), 0.87 (s, 9H), 0.15 (s, 3H), 0.10 (s, 3H). 13C NMR (100 MHz, CDCl3) δC
207.34, 206.06, 174.01, 172.78, 171.24, 170.63, 138.37, 135.58, 135.56, 135.25, 133.72, 133.51,
129.53, 127.56, 127.53, 116.73, 114.77, 110.81, 102.30, 98.90, 81.57, 77.32, 77.00, 76.68, 75.36,
75.09, 73.94, 73.43, 73.37, 72.34, 68.86, 68.72, 65.72, 65.09, 65.01, 62.84, 38.11, 37.69, 36.83,
36.34, 33.72, 32.04, 29.72, 28.64, 27.97, 27.85, 26.80, 25.80, 22.94, 20.83, 19.19, 17.71, 16.34, 4.46, -4.52.

Ring-Closed Intermediate 3.24. To a solution of diene 3.23 (2.49 g, 1.0 eq) in DCM (500
mL) was added Hoveyda-Grubbs catalyst 2nd generation (0.26 g, 0.2 eq) in one portion at room
temperature. The reaction mixture was refluxed for 4 h. At this point, TLC (silica, 1:2 EtOAc–
hexanes) showed the reaction was complete. The reaction was cooled to ambient temperature and
then concentrated. Flash chromatography (silica, EtOAc–hexanes, 1:2 → 1:1) gave the mixture
of isomers as a colorless syrup. The obtained isomer was subjected to hydrogenation in next step
and the product was fully characterized. To a solution of the cycloalkene isomers in EtOH (50
mL) was added 10% Pd/C (0.5 g) in one portion at room temperature. The reaction was then
stirred under an atmosphere of hydrogen for 4 hours at the same temperature. At this point, TLC
(silica, 1:2 EtOAc–hexanes) showed the reaction was complete. The reaction mixture was
filtered thru a pad of celite using EtOAc as the eluent and the resulting filtrate concentrated.
Flash chromatography (silica, EtOAc–hexanes, 1:2 → 1:1) gave compound 3.24 (1.32 g, 54%
over 2 steps) as a colorless syrup. 1H NMR (400 MHz, CDCl3) δH 7.68 – 7.66 (m, 4H), 7.43 –
7.35 (m, 6H), 5.11 – 5.03 (m, 2H), 4.95 – 4.84 (m, 3H), 4.17 (d, J = 7.7 Hz, 1H), 4.03 – 3.88 (m,
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8H), 3.82 (dd, J = 9.2, 3.4 Hz, 1H), 3.60 – 3.58 (m, 2H), 3.47 – 3.34 (m, 3H), 2.79 – 2.75 (m,
4H), 2.64 – 2.55 (m, 5H), 2.44 – 2.38 (m, 2H), 2.17 (d, J = 1.7 Hz, 6H), 2.08 (s, 3H), 1.98 – 1.92
(m, 1H), 1.70 – 1.26 (m, 15H), 1.06 (s, 9H), 0.95 (d, J = 6.4 Hz, 3H), 0.88 (s, 9H), 0.18 (s, 3H),
0.13 (s, 3H). 13C NMR (100 MHz, CDCl3) δC 206.83, 206.24, 175.34, 172.37, 171.25, 170.70,
135.63, 135.62, 133.97, 133.77, 129.51, 129.49, 127.55, 127.51, 111.08, 102.58, 98.93, 82.97,
77.32, 76.68, 74.99, 74.89, 74.56, 73.54, 73.33, 72.13, 68.75, 67.35, 66.07, 64.68, 64.52, 62.26,
53.79, 37.93, 37.77, 35.70, 31.95, 31.65, 29.83, 29.80, 29.77, 29.26, 28.92, 28.24, 27.90, 26.88,
25.83, 23.50, 23.06, 20.89, 19.25, 17.61, 16.43, -4.10, -4.56.

Compound 3.25. CMPI (419 mg, 1.5 eq), DMAP (66.7 mg, 0.5 eq) and NEt3 (1.11 g,
1.53 mL, 10 eq) were added to a solution of 3.24 (1.28 g, 1 eq) and cinnamic acid (243 mg, 1.5
eq) in dry DCM (30 mL) at -10 oC. The reaction was allowed to slowly warm to ambient
temperature and stirred overnight. At this point, TLC (silica, 2:1 Hex–EtOAc) showed the
reaction was complete. The reaction mixture was diluted with DCM (30 mL) washed with sat.
NaHCO3 (30 mL) and extracted with DCM (30 mL). The combined organic extracts were dried
over Na2SO4. Evaporation of the solvent followed by purification of the residue by column
chromatography (silica, Hexanes−EtOAc, 3:1 → 1:2) to give 3.25 (1.31 g, 92%) as a colorless
syrup. 1H NMR (400 MHz, CDCl3) δH 7.70 – 7.66 (m, 4H), 7.53 – 7.51 (m, 2H), 7.42 – 7.38 (m,
9H), 6.36 (d, J = 16.0 Hz, 1H), 5.29 – 5.20 (m, 3H), 5.01 – 4.95 (m, 2H), 4.36 (dd, J = 12.3, 2.6
Hz, 1H), 4.26 (d, J = 7.6 Hz, 1H), 4.07 (dd, J = 12.3, 2.2 Hz, 1H), 3.99 – 3.82 (m, 7H), 3.69 –
3.59 (m, 3H), 3.48 – 3.42 (m, 1H), 2.79 – 2.76 (m, 2H), 2.70 – 2.64 (m, 2H), 2.61 – 2.47 (m,
5H), 2.39 – 2.35 (m, 2H), 2.15 (s, 3H), 2.09 (s, 6H), 2.01 – 1.96 (m, 1H), 1.73 – 1.26 (m, 15H),
1.07 (s, 9H), 0.96 (d, J = 6.4 Hz, 3H), 0.91 (s, 9H), 0.20 (s, 3H), 0.14 (s, 3H). 13C NMR (100
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MHz, CDCl3) δC 206.16, 206.05, 172.94, 171.88, 171.12, 170.66, 165.00, 146.07, 135.62,
135.61, 134.09, 133.88, 133.60, 130.52, 129.55, 129.52, 128.82, 128.26, 127.59, 127.54, 116.76,
111.23, 102.24, 98.86, 82.67, 77.32, 76.68, 74.29, 74.04, 73.50, 73.05, 72.19, 71.89, 68.86,
68.46, 66.02, 64.52, 64.49, 61.63, 37.76, 37.68, 34.60, 31.93, 31.24, 30.01, 29.77, 29.56, 29.24,
29.00, 28.20, 27.91, 27.82, 26.87, 25.88, 23.92, 22.93, 20.84, 19.23, 17.73, 16.37, -4.31, -4.50.

Preparation of Triol Intermediate

Diol 3.27. Hydrazine acetate (0.535 g, 6.0 eq) was added in one portion to a solution of
compound 3.25 (1.26 g, 1.0 eq) in 2:1 DCM/MeOH (16 mL) at room temperature. The reaction
mixture was stirred for 2 hr, at which point TLC (silica, 2:1 Hex–EtOAc) showed the reaction
was complete. Then the reaction was quenched with sat. aq. NaHCO3 (20 mL) and extracted
with DCM (25 mL x 2). The combined organic extracts were dried over Na2SO4, evaporated and
purified by column chromatography (silica, Hex–EtOAc, 3:1→ 1:1) to afford compound 3.27
(717 mg, 67%) as a colorless syrup. 1H NMR (400 MHz, CDCl3) δH 7.71 – 7.68 (m, 4H), 7.55 –
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7.53 (m, 2H), 7.45 – 7.38 (m, 9H), 6.46 (d, J = 16.0 Hz, 1H), 5.12 – 5.05 (m, 2H), 4.62 (d, J =
7.7 Hz, 1H), 4.40 (d, J = 7.6 Hz, 1H), 4.25 (dd, J = 11.9, 3.8 Hz, 1H), 4.14 – 4.08 (m, 1H), 3.95
– 3.80 (m, 9H), 3.77 – 3.63 (m, 5H), 3.51 – 3.42 (m, 2H), 2.66 (d, J = 2.4 Hz, 1H), 2.35 – 2.30
(m, 2H), 2.11 (s, 3H), 2.05 – 1.90 (m, 3H), 1.76 – 1.55 (m, 5H), 1.43 – 1.25 (br, m, 10H), 1.07 (s,
9H), 1.02 (d, J = 6.4 Hz, 3H), 0.92 (s, 9H), 0.22 (s, 3H), 0.18 (s, 3H). 13C NMR (100 MHz,
CDCl3) δC 173.06, 170.58, 166.17, 146.13, 135.64, 135.62, 134.15, 133.79, 133.61, 130.50,
129.60, 129.60, 128.86, 128.21, 127.59, 127.56, 117.12, 111.21, 103.34, 102.14, 80.97, 78.13,
77.32, 77.20, 76.68, 75.99, 73.46, 72.99, 72.69, 72.40, 71.46, 68.71, 65.74, 64.59, 64.46, 63.61,
60.34, 35.08, 31.60, 31.31, 29.70, 29.02, 28.53, 26.87, 25.86, 24.04, 22.71, 21.00, 20.75, 19.25,
17.84, 16.37, 14.16, -4.37, -4.63.

Intermediate 3.28. A solution of compound 3.27 (711 mg, 1.0 eq), tiglic acid (70.8 mg,
1.1 eq) DCC (159 mg, 1.2 eq), and DCM (20 mL) were cooled to -10 oC. Then DMAP (7.8 mg,
0.1 eq) was added to the solution in portion and the reaction allowed to slowly warm to RT
overnight. TLC (silica, Hex-EtOAc, 2:1) showed the reaction to be mostly complete. The
solvent was partially removed, then Hex (16 mL) and Et2O (8 mL) were added, then stirred for
20 min to precipitate the DCU byproduct. The mixture was filtered through a pad of Celite using
cold Et2O (20 mL) as the eluent, and the filtrate was concentrated under reduced pressure. The
residue was purified by column chromatography (silica, Hex-EtOAc 6:1 → 1:1) to give
intermediate 3.28 (512 mg, 67%) (603 mg, 79% BORSM). 1H NMR (400 MHz, CDCl3) δH 7.71
– 7.68 (m, 4H), 7.53 – 7.50 (m, 2H), 7.45 – 7.38 (m, 9H), 6.85 – 6.80 (m, 1H), 6.36 (d, J = 16.0
Hz, 1H), 5.34 – 5.20 (m, 2H), 5.04 (d, J = 3.1 Hz, 1H), 4.70 (d, J = 7.6 Hz, 1H), 4.39 (d, J = 7.6
Hz, 1H), 4.23 (dd, J = 11.9, 3.7 Hz, 1H), 4.08 (dd, J = 11.9, 4.6 Hz, 1H), 3.96 – 3.67 (m, 12H),
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3.61 – 3.56 (m, 1H), 3.49 (q, J = 6.36 Hz, 1H), 2.39 – 2.25 (m, 2H), 2.09 (s, 3H), 2.05 – 1.88 (m,
2H), 1.76 – 1.72 (m, 7H), 1.66 – 1.54 (m, 5H), 1.34 (br, 10H), 1.08 (s, 9H), 1.01 (d, J = 6.4 Hz,
3H), 0.89 (s, 9H), 0.21 (s, 3H), 0.17 (s, 3H). 13C NMR (100 MHz, CDCl3) δC 173.06, 170.70,
167.47, 165.60, 146.03, 138.10, 135.66, 134.10, 133.80, 133.62, 130.51, 129.64, 128.85, 128.24,
127.91, 127.62, 127.59, 116.87, 111.25, 103.82, 102.22, 80.98, 78.40, 77.32, 76.68, 74.43, 72.95,
72.83, 72.69, 72.26, 69.73, 68.74, 65.70, 64.60, 64.48, 63.56, 35.06, 31.68, 31.38, 29.69, 29.11,
28.56, 26.90, 25.78, 24.03, 22.80, 20.83, 19.26, 17.82, 16.36, 14.35, 11.97, -4.43, -4.55.

Triol 3.29. To a stirred solution of compound 3.28 (504 mg, 1.0 eq) in MeOH (10 mL)
and H2O (0.1 mL) was added CSA (19.7 mg, 0.2 eq) at RT. The reaction was stirred for 12 hours
at which point TLC (silica, Hex-EtOAc, 2:1) showed the SM to be consumed. After the initial
reaction was complete, to the same pot was added TBAF (1M in THF, 8.48 mL, 20 eq) and
AcOH (2.9 mL, 50 eq) at 0 oC. The reaction was allowed to warm to RT and stir overnight at
which point TLC (silica, Hex-EtOAc, 1:1) indicated that the reaction was fully deprotected. The
reaction mixture was then diluted with Et2O (20 mL) and washed with 1M HCl (10 mL), then
saturated aqueous NaHCO3 (10 mL) and brine (10 mL). The aqueous layers were extracted with
Et2O (20 mL x 2) and the combined organic layers were dried over Na2SO4, filtered, and
concentrated to dryness. The residue was then purified via column chromatography (silica, HexEtOAc 2:1 → 0:1) to give compound 3.29 (275 mg, 82%). δH 7.64 (d, J = 16.0 Hz, 1H), 7.52 –
7.49 (m, 2H), 7.40 – 7.39 (m, 3H), 6.94 – 6.89 (m, 1H), 6.35 (d, J = 16.0 Hz, 1H), 5.36 (t, J = 9.8
Hz, 1H), 5.19 (d, J = 3.1 Hz, 1H), 5.07 (t, J = 9.5 Hz, 1H), 4.66 (d, J = 7.8 Hz, 1H), 4.53 (dd, J
= 12.5, 3.1 Hz, 1H), 4.42 (d, J = 7.7 Hz, 1H), 4.16 – 4.09 (m, 2H), 3.92 (dd, J = 9.6, 3.5 Hz, 1H),
3.83 – 3.47 (m, 7H), 2.89 – 2.44 (m, 7H), 2.19 (s, 3H), 2.07 – 2.05 (m, 2H), 1.79 – 1.61 (m,
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10H), 1.45 – 1.21 (m, 12H), 0.98 – 0.86 (m, 2H). 13C NMR (100 MHz, CDCl3) δC 209.85,
171.72, 171.30, 169.40, 165.32, 146.19, 140.42, 133.94, 130.67, 128.89, 128.25, 127.40, 116.63,
106.13, 101.51, 84.62, 83.61, 74.18, 72.49, 72.20, 69.40, 67.10, 65.09, 61.82, 60.36, 41.75,
37.39, 31.52, 28.96, 28.63, 28.27, 25.39, 23.07, 21.00, 20.82, 16.21, 14.63, 14.16, 13.66, 11.89.
HRMS for C40H54NaO16 (M+Na)+ 813.3304. Found: 813.3292

Completion of Intermediate for Analog Synthesis

Diol 3.30. To a stirred solution of triol 3.29 (265 mg, 1 eq) and imidazole (68.4 mg, 3 eq)
in DCM (10 mL) was added TBDPSCl (276 mg, 3 eq) and DMAP (20.5 mg, 0.5 eq) at 0 oC. The
reaction was allowed to warm to RT after addition of TBDPSCl and was left to stir overnight at
which point TLC (EtOAc-hexanes, 1:1) showed all the SM had been consumed and one major
product was observed. The reaction mixture was transferred to a separatory funnel and washed
with water (2 x 10 mL). The aqueous layers were extracted with DCM (2 x 10 mL) and the
combined organic layers were washed with brine (10 mL), dried over sodium sulfate, filtered,
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and concentrated to dryness. The residue was purified via column chromatography (silica,
EtOAc-Hexanes, 1:2 → 1:0) to give the desired compound 3.30 (297 mg, 86%). 1H NMR (400
MHz, CDCl3) δH 7.70 – 7.68 (m, 4H), 7.63 (d, J = 16.0 Hz, 1H) 7.52 – 7.50 (m, 2H), 7.46 – 7.37
(m, 9H), 6.92 – 6.87 (m, 1H), 6.35 (d, J = 16.0 Hz, 1H), 5.29 (t, J = 9.8 1H), 5.11 – 5.06 (m, 2H),
4.59 (br, 1H), 4.54 (d, J = 7.8 Hz, 1H), 4.43 (dd, J = 12.4, 3.1 Hz, 1H), 4.39 (d, J = 7.7 Hz, 1H),
4.02 – 3.98 (m, 2H), 3.90 – 3.84 (m, 2H), 3.75 – 3.57 (m, 6H), 2.76 – 2.43 (m, 6H), 2.16 (s, 3H),
1.76 – 1.61 (m, 14H), 1.34 – 1.22 (m, 7H), 1.07 (s, 12H). 13C NMR (100 MHz, CDCl3) δC
210.05, 171.71, 171.57, 169.05, 165.38, 146.11, 140.00, 134.00, 133.90, 133.70, 130.64, 129.64,
129.61, 128.90, 128.26, 127.62, 127.58, 127.51, 116.72, 105.84, 101.06, 83.10, 80.64, 77.20,
76.12, 74.21, 72.68, 72.46, 72.43, 68.78, 67.45, 66.01, 61.86, 41.77, 37.61, 36.62, 31.32, 29.18,
29.07, 28.40, 26.91, 24.77, 24.67, 23.59, 20.88, 19.29, 16.27, 14.60, 11.94.

Protected intermediate 3.31. DCC (232 mg, 4.0 eq) was added in one portion to a 0 ºC
DCM (10 mL) solution of 3.30 (289 mg, 1.0 eq), chloroacetyl acid (127 mg, 4.0 eq) and 4dimethylaminopyridine (34.3 mg, 1.0 eq). The reaction was allowed to warm to ambient
temperature and stirred overnight. At this point, TLC (silica, 1:1 EtOAc–hexanes) showed the
reaction was complete. The reaction mixture was diluted with ether (10 mL) and hexanes (5 mL),
stirred for 20 minutes then filtered thru a pad of celite using ether (10 mL) as the eluent and the
filtrate concentrated in vacuo. The residue was purified by column chromatography (silica,
EtOAc–hexanes, 1:5 → 1:2) gave compound 3.31 (302 mg, 91 %). Some DCU remained after
purification but the crude material was carried forward to the next step and characterized
following deprotection.
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Compound 3.32. To a stirred solution of 3.31 (290 mg, 1.0 eq) in MeOH (10 mL) was
added CSA (11.4 mg, 0.2 eq) at 0 oC. The reaction was allowed to warm to RT as it stirred
overnight. TLC (Silica, 1:1 EtOAc–hexanes) indicated that the reaction was complete. The
reaction mixture was diluted concentrated and then diluted with DCM (15 mL) and washed with
a saturated solution of NaHCO3 (10 mL). The aqueous layer was extracted with DCM (2 x 10
mL) and the combined organic layers were washed with brine (10 mL), dried over sodium
sulfate, filtered and concentrated to dryness. The residue was purified via column
chromatography (Silica, EtOAc–hexanes, 1:4 → 1:1) to give compound 3.32 (183 mg, 79%). 1H
NMR (400 MHz, CDCl3) δH 7.62 (d, J = 16 Hz, 1H), 7.51 – 7.49 (m, 2H), 7.40 – 7.39 (m, 3H),
6.82 – 6.78 (m, 1H), 6.32 (d, J = 16.0 Hz, 1H), 5.35 (p, J = 8.4 Hz, 2H), 5.19 (m, J = 3.1 Hz,
1H), 5.13 – 4.96 (m, 3H), 4.52 – 4.47 (m, 2H), 4.20 – 4.14 (m, 3H), 4.05 – 3.83 (m, 6H), 3.65 –
3.56 (m, 4H), 3.17 – 3.16 (m, 1H), 2.99 – 2.92 (m, 1H), 2.75 – 2.40 (m, 6H), 2.20 (s, 2H), 1.96 –
1.93 (m, 1H), 1.75 – 1.58 (m, 18H), 1.37 – 1.22 (m, 20H), 0.90 – 0.87 (m, 2H).

Synthesis of Tail-Modified Analogs

Analog 3.33. To a stirred solution of compound 3.32 (20.0 mg, 1.0 eq) in dry DCM (5
mL) was added 1-methyl-2-chloropyrdium iodide (CMPI) (1.69 g, 2.0 eq), DMAP (203 mg, 0.5
eq), and butanoic acid (0.781 g, 1.5 eq). After the reaction was cooled to 0 oC, NEt3 (3.36 g,
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4.62 mL, 10 eq) was added and the reaction was allowed to slowly warm to RT over 1-2 hrs. At
this point TLC showed the reaction to be complete (silica, Hex‒EtOAc 1:1). The reaction
mixture was then concentrated and re-dissolved in ethanol (5 mL). To the solution was added
DABCO (4.8 mg, 2.0 eq) at rt. The reaction was stirred for one hour, at which point TLC (silica,
1:1 EtOAc–hexanes) showed it was complete. The reaction mixture was diluted with DCM (5
mL), washed with 1M HCl (5 mL) and saturated aqueous NaHCO3 (5 mL). The aqueous layer
was extracted with DCM (2 x 5 mL). The combined organic layer was dried over Na2SO4 and
concentrated under reduced pressure. The residue was purified by column chromatography
(silica, EtOAc–hexanes, 1:3 → 1:0) to give compound 3.33 (12.7 mg, 70%). 1H NMR (400
MHz, CDCl3) δH 7.65 (d, J = 16 Hz, 1H), 7.53 – 7.50 (m, 2H), 7.40 – 7.39 (m, 3H), 6.94 – 6.90
(m, 1H), 6.36 (d, J = 16.0 Hz, 1H), 5.35 – 5.31 (m, 2H), 5.16 – 5.07 (m, 3H), 4.64 – 4.48 (m,
1H), 4.49 – 4.41 (m, 1H), 4.23 – 4.12 (m, 3H), 3.96 – 3.68 (m, 10H), 2.75 – 2.21 (m, 8H), 2.18
(s, 2H), 2.05 – 2.01 (m, 1H), 1.96 – 1.93 (m, 1H), 1.77 – 0.86 (m, 38H). HRMS for C44H60NaO17
(M+Na)+ 883.3723. Found: 883.3716

Analog 3.34 (10.8 mg, 57%). Synthesized from compound 3.32 (20.0 mg) in the same
method as above. HRMS for C47H58NaO17 (M+Na)+ 917.3566. Found: 853.3565
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